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“Gli uomini sono artefici del proprio destino: 
possono commettere sempre gli stessi errori, 
possono fuggire costantemente da ciò che 
desiderano, e che magari la vita offre loro in modo 
generoso; oppure possono abbandonarsi al destino 
e lottare per i propri sogni accettando il fatto che si 
presentano sempre nel momento giusto.” 
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1. Introduction  
 
In recent decades nano-sciences have polarized the attention of researchers, 
thanks to their potential of innovation that can be applied in many scientific and 
technological field of knowledge1–6. Particles with at least one dimension less 
than 100 nm in the form of nanoparticles (NPs), nanofibers and 
nanocomposites, indeed find application in electronics, biotechnology, medical 
sciences and many other technological fields. Products of this innovation are 
already available on the market or shortly will be, improving the quality of our 
life. When reduced to the nano-scale, indeed, materials may reveal attractive 
and unexpected properties, different from those of the bulk counterparts, which 
can be exploited to realize new or better materials7; in particular, in medical 
science nanomaterials are expected to have a large potential to create products 
able to increase specificity, accuracy and efficacy of diagnosis and treatment 
of diseases8. 
In particular, among the others, magnetic nanoparticles (MNPs) represent one 
of the most promising materials for biomedical application, thanks to their 
unique properties9. First of all, they share in common with all the NPs two 
important characteristics: they have a size comparable to that of many 
biological entities of interest as protein, DNA, and cell organelles; they have high 
surface area and large surface-to-volume ratio due to their nanometric size, 
which assure the possibility to maximize the interaction with other elements. 
However unlike other kind of nanometric materials, MNPs possess the unique 
properties of superparamagnetic behaviour10. When the size of ferro- or 
ferrimagnetic particles is lower than a critical size d! which depending on the 
type of material varies between tens to few hundreds of nanometers, they 
become single domain, i.e. the formation of magnetic domains is no longer 
energetically favoured, so that they are characterized by a single magnetic 
  2
moment given by the sum of all the spins included in the NP. This magnetic 
moment will freely fluctuate like in a paramagnet (superparamagnetism) or will 
be blocked along certain favoured crystallographic directions (ferromagnetic-
like behaviour) depending on whether the thermal energy is larger or smaller 
than the energy barrier separating these directions. This energy barrier is 
determined by the magnetic anisotropy of the material itself and, as a first 
approximation, is proportional to the volume of the MNPs. 
MNPs find11 application in biomedicine both in the diagnosis, as magnetic 
resonance imaging contrast enhancement agent12, and in the therapy as drug 
delivery (DD) carrier13 as heat mediator in magnetic fluid hyperthermia (MFH)8,14. 
They also find large application in biotechnology where thanks to their 
properties they are used in high efficiency detection and removal devices, in 
immunoassay tests, for cells or proteins purification and separation, water or 
biological fluids detoxification13,15–19. Since applications in medicine requires 
that the use of a biocompatible materials, iron oxides are to the date the mostly 
investigated MNPs; in particular, in the family of iron oxide magnetite, Fe"O#	and 
maghemite,	γ ∙ Fe$O", which can potentially follow endogenous pathways of 
degradation and be reused by the body, have the best magnetic properties.  
The most fascinating characteristic of MNPs for application in biomedicine is 
the unique combination of the moving, sensing and heating capabilities in a 
single element. Indeed, MNPs offer: 
• the possibility to control remotely the MNPs using a static magnetic field 
(SMF) gradient; 
• the ability of the magnetic moment of MNPs to interact with nearby 
nuclear spin of water protons, modifying their relaxation rate in magnetic 
resonance imaging (MRI) analysis; 
• the capability to release heat when exposed to an Alternating Magnetic 
Field (AMF) of the right frequency and intensity. 
 
 
 3 
The first characteristic allows the separation from a biological fluid of an 
element (protein, DNA, heavy metal, pathogen, bacteria, etc.) bound to the 
MNPs, by simple application of a permanent magnet, for analytical tests or for 
blood purification. The surface of the MNPs indeed can be functionalized to 
react specifically with an element, for instance a bacterial antibody, so that 
MNPs they can selectively bind only this pathogen, allowing its separation from 
the rest of the mixture by means of an SMF as described in Figure 1.1. 
Furthermore, as shown in Figure 1.2, using a specific SMF gradient it is possible 
to concentrate MNPs in a target area near the surface of a body and, for 
example, transport a drug bound to the nano-device with greater precision than 
common systemic drug administration, reducing the amount of drugs required 
for the treatment. In the same way it is possible to deliver bioengineered 
magnetic scaffolds for tissue repair20. 
 
Figure 1.1: a) MNPs mixed into a solution bind specifically one of the component; b) the mixture reacted 
can be put into a becker or in a continuos flow; c) a strong SMF gradient attracts the MNPs, d) separation 
from the mixture. 
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Figure 1.2: MNPs with drug bound onto their surface coating, flows into the blood vessels and concentrate 
into a target area where a strong SMF gradient is applied. 
 
The second feature can be used to overcome one of the limits associated with 
the use of MRI technique. Indeed, even if MRI is widely used in medical clinic 
to investigate the anatomy and physiology of the body, often a contrast agent 
(CA) is needed to increase the natural contrast between healthy and 
pathological tissues, like tumour lesions, oedema, soft tissue damages and so 
on. As a matter of fact, MRI provides images of the density distribution of 
protons or other nuclei through the application of appropriate magnetic field 
gradients and radiofrequency pulse sequences21. When the pulse is applied the 
proton spin magnetization, m rotates and then relaxes back to the equilibrium 
values with two typical relaxation times, called T1 and T2, as shown in Figure 
1.3. MRI exploits the contrast created by different nuclear spin-lattice (T1) and 
spin-spin (T2) relaxation times which characterizes water protons of molecules 
contained in different tissues to visualize the interior of the body. When the 
natural image contrast is not enough to highlight the presence of the diseased 
tissue, it is necessary to use a CA that induces variation of either T1 or T2 or 
both. CA are usually classified into two groups: those that increase the 
longitudinal relaxation rate, R% = 1	/	T% and those that increase the transverse 
 
 
 5 
relaxation rate, R$ = 1	/	T$. T% agents are called positive CAs since their effect 
leads to an increase of the intensity of the signal (brighter region) in the areas 
where they are located. Conversely, T$ agents are defined as negative CAs, as 
they cause a reduction in the intensity of the signal (darker region) in areas 
where they accumulate, Figure 1.4. The paramagnetic metal complexes 
belonging to the lanthanide family (Gd, Dy, Tb) are the principal representatives 
of T% agents, while superparamagnetic iron oxide MNPs are the best example 
of T$ agents. 
 
Figure 1.3: a) Relaxation of a magnetic moment, m, of a proton nuclear spin after a RF pulse; The in plane 
component, mxy, vanishes with a characteristic time T2, while m recovers its initial value along the static filed, 
mz with a characteristic time T1 b) Relaxation time of longitudinal (upper panel) and transversal (lower panel) 
magnetizations after the RF pulse, different local environments influence the time at which the magnetization 
recover the initial value. The darker lines show the effect of a paramagnetic or superparamagnetic centre on 
the water proton spins (shortening of the relaxation times). 
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Figure 1.4: Different action of positive (left) and negative (right) CAs on T1 and T2 weighted MRI. 
 
CAs based on dextran coated assembly of superparamagnetic Iron Oxides 
nanoparticles with a total average diameter between 20 and 150 nm are also 
commercially available. In Table 1.1, some examples of clinically approved CA 
for MRI are reported22. 
 
Commercial name Generic Name MRI Target 
Feridex® *, Endorem® Ferumoxides Liver, Spleen 
Resovist® Ferucarbotran Liver 
Sinerem™, 
Combidex® * 
Ferumoxtran-
10 
Limph node 
methastases 
Lumirem®, 
GastroMARK® * 
Ferumoxil Bowel 
Feraheme® * Ferumoxitol Vasculature 
Table 1.1: Iron Oxide (Fe2O3) based MNPs available as CAs in MRI; (*Approved by FDA)23,24 
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Last but not least MNPs can be used as heat mediators in hyperthermic 
treatments of tumours, i.e. when irradiated by an AMF of proper frequency and 
amplitude dissipate the energy accumulated in the reversal of the magnetization 
as heat. Hyperthermia treatments take inspiration from ancient wisdom of 
empirical evidences about fever hyperthermia25, while it is ca. 150 years ago 
that Busch first reported experimental evidences that tumours cease to grow 
when subjected to temperature above 42 °C whilst healthy tissues are not 
affected by such temperatures26. 
In order to better understand the principle of hyperthermia treatment, we must 
point out that unlike healthy tissues, the neoplastic ones are characterized by 
an irregular and chaotic vasculature. Tumour cells overexpress growth factors 
that stimulate the creation of new blood vessels, preventing the organization of 
a bloodstream as ordered as in healthy tissues, which often induces stagnation 
of blood. This pathological condition causes is tumours hypoxia, low pH and 
inability of dissipating heat efficiently, making them more susceptible to thermal 
damages25. As a further consequence, the endothelial cells of pathological 
blood vessels do not form tight junction but have fenestrations that allow 
plasma to invade and be restrained in the extracellular matrix. As a 
consequence objects with size less than 200 nm can cross the vascular 
fenestrations and accumulate at the tumour site, thus allowing a natural passive 
targeting of the MNPs. This effect is referred as Enhanced permeability and 
Retention effect (EPR).  
Hyperthermic treatment are commonly based on the local application of 
microwaves, radio-waves either with or without magnetic needles implanted 
into the target site, often associate with therapies involving ionizing radiation27. 
Disadvantages of these strategies are the undesired side-effects such as 
ionization of genetic material (radiation), lack of selectiveness (microwaves and 
radio-waves), that affect the surrounding healthy tissues and invasiveness (use 
  8
of antennas). Although they have successfully been applied to destroy 
malignant tissues effectiveness of treatments is rather limited. 
MFH in principle allow selective heating by localization of the heating source 
(MNPs) into the tumour tissue and induction of heat release by application of 
an external AMF. In MFH therapy, MNPs are delivered near or inside the tumor 
cells and, depending on the temperature reached, it is possible to cause an 
irreversible cell damage without tissue necrosis (41-46°C) or the complete 
necrosis of the tumor by thermoablation (more than 46°C, up to 56°C)28,29. It has 
been also demonstrated that, in the case of moderate temperature increase (41-
43°C), the hyperthermia treatment enhances the effect of conventional 
therapies, as chemotherapy or radiotherapy30. This represents a significant 
improvement of tumour therapy compared to the previously described heating 
techniques. The first application of MFH dates back to 70 years ago when 
Gilchrist et al.31 presented an experimental work on MFH: they resected lymph 
nodes of a dog and heated up ex vivo by application of an AMF to iron oxide 
micro-particles injected into the tumour. More recently, Jordan et al. 
demonstrated the feasibility of MFH in clinical in vivo trials of MFH treatment in 
patient suffering glioblastoma32 and prostate cancer33,34. They used a 
combination of radiotherapy and heating produced by 12 nm amino-silane 
coated -."/# MNPs directly injected into the tumour mass at high doses (ca. 
50 mg/cm3); as major result they found no systemic toxicity, long and high 
MNPs retention into the tumour tissues and small but significant increase of the 
expectation of life with slightly and temporally morbidity.33,35 
The attractiveness of MFH treatment relies in its potential for greater selectivity 
and effectiveness and reduced side-effects compared to common 
hyperthermia techniques. An additional advantage of using MNPs is the 
possibility to exploit them as diagnostic and therapeutic agents simultaneously, 
with a theranostic approach. Nevertheless, there are still several issues that 
need to be addressed to exploit all the potentialities offered by this approach. 
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On one hand, MNPs used to date have poor magnetic properties and, 
consequently, also poor ability to release heat and to enhance contrast in MRI 
images. However, nowadays chemists have developed different techniques 
which allow the production of MNPs with much improved characteristic. On the 
other hand, a major drawback is represented by the stability of MNPs in the 
human body. In this context, as well described by M. Ferrari in the review 
“Cancer nanotechnology: opportunities and challenges”36, and in his following 
works37, one of the open issues is the understanding of the bio-distribution 
mechanisms of MNPs, in order to develop effective strategies to overcome the 
many physiological barriers to reach the target. For efficiently designing and 
realizing a nano-device with the best performance and multiple features, it is in 
fact important to be able to deliver it to the specific place of interest. 
In particular, some of main barriers to be overcome are: 
• the biological filters such liver, spleen and kidney; 
• the reticulo-endothelial system; 
• the abnormal flow of blood, which can hamper MPNs to reach the target; 
• the increased osmotic pressure within cancer lesion; 
• the extracellular matrix; 
• the membranes of cells and nuclei. 
 
A crucial element for approaching all the limitations imposed by the human 
physiology is the surface coating of MNPs. Indeed, the coating determines the 
interaction of MNPs with the cell and all the elements of the physiological 
environment, and, at end, it is the mean to equip the MNPs with multiple 
functionalities. The main goal of the surface coating is to protect the magnetic 
core from degradation while preserving its properties over time. At the same 
time, it must allow overcoming the physiological barriers and disguising from 
the immune system defences. Poly Ethylene Glycol (PEG), for instance, is well 
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known significantly increasing the half-life circulation time by shielding MNPs 
from RES captures38,39. 
As shown in Figure 1.5, a medical nano-device based on MNPs is designed to 
be firstly covered by a polymer or molecule to isolate it from the outer 
environment. As a second step, a wide variety of molecules and polymers, that 
enrich MNP's ability and functionality, can be grafted on the coating layer. To 
track bio-diffusion and nano-device's fate, many different tracers can be linked 
to the coating, such as radioactive atoms, fluorescent dye, CAs molecule for 
Positron Emission Tomography (PET), or Single Photon Computed Tomography 
(SPECT)40,41. Targeting agent as peptide, aptamer, antibody and protein can 
also be added to selectively target the diseased tissue40, while pH-sensitive 
polymer can modify the MNPs stability once in the acid environment of tumour 
tissues42. Drugs can be loaded into the polymer coating or grafted onto it, and 
delivered to the target13,40; while nucleic acid, Tumour-Associated Antigens, and 
Tumour-Associated Carbohydrate Antigens can be released for immunotherapy 
treatment43. 
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Figure 1.5: Sketch of different functionalities that can be implemented into a MNP-based device 
 
This thesis moves in this complex scenario, the main target being the synthesis 
and characterization of a protein-based multifunctional MNPs for simultaneous 
early diagnosis and therapy of cancer (theranostic approach44). To realize this 
goal we coupled a MNP with tailored physical properties for use as heating 
agent in magnetic fluid hyperthermia and contrast agent for diagnostic imaging, 
to the shell of human ferritins (Fn), in order to exploit the multiple advantages 
provided by this endogenous protein, included the possibility of using it as 
selective drug carrier towards tumor cells.  
Human ferritin is a highly symmetrical ubiquitary protein consisting of 24 
subunits that self-assemble into a shell-like sphere, with external and internal 
diameters of 12 and 8 nm, respectively, enclosing a hollow cavity used for 
storing iron. The choice of Fn to build up a nano-system for theranostic 
applications is based on the many appealing features this endogenous protein 
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possesses. First Fn is fully biocompatible and it does not activate the immune-
inflammatory response, avoiding many of the physiological barrier previously 
cited. Furthermore HFn can provide a targeting function, as many cancer cell 
lines over-express the transferrin membrane receptor TfR1. TfR1 recognizes the 
H ferritin sub-unit causing its internalization within the tumour cell. Moreover, 
the external surface of ferritin can be easily functionalized with specific targeting 
agent or drugs, both by genetic recombination and chemical reaction on the 
numerous thiol and amine residues of cysteine, lysine and glycine. Finally, the 
hollow cavity of HFn can be filled with drugs, such as doxorubicin by simple 
self-assembly techniques. 
For the realization of the MNP – HFn system we first synthesized magnetite 
MNPs by thermal decomposition of a metal-organic precursor, iron 
acetylacetonate, in high boiling solvent. Several attempts were performed in 
order to obtain highly crystalline, pure magnetite MNPs with a size in the 12-15 
nm range. This particular size corresponds to the best compromise between a 
large heating efficiency in magnetic fluid hyperthermia and colloidal stability. 
HFns were then conjugated to the inorganic nanoparticles through a 
heterobifunctional linker, properly chosen to react selectively with thiol 
functional groups. 
In vitro and preliminary in vivo studies were carried out on selected tumor cell 
lines (MDA-MB231, PC3) to assess bio-distribution, toxicity and genotoxicity of 
the nano-system. Antitumor hyperthermic efficacy was also evaluated by 
checking cancer cell viability after incubation with MNP-HFn and application of 
an alternating magnetic field of frequency and amplitude similar to those used 
in clinical treatment. The relaxometric properties were also measured to verify 
the capability of the nano-system to act as CA in MRI analysis. Finally, we 
investigated the possibility of using the HFn cavity as carrier for a cytotoxic 
drug, doxorubicin. Overall, the obtained results show that the MNP-HFn system 
is a highly promising platform for theranostic application. In fact, we 
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demonstrated that MNP-HFn has a very good biocompatibility and high stability 
in physiological media, and, most importantly, it is an efficient heat mediator for 
MFH both in vitro and in vivo and it enhances the contrast in MRI images. 
This thesis is organized as follows: in the first chapter the synthesis by thermal 
decomposition of MNPs and their characterization is presented. This part of the 
work was aimed at identifying the synthesis conditions to obtain MNPs with 
optimal physical and chemical characteristic for use in nanomedicine. In 
Chapter 3 we will present the investigation on the efficiency of MNP-HFn in 
releasing heat under the AMF action, and in increasing the relaxation rate of 
nuclear spin in MRI. The synthesis and characterization of the protein-inorganic 
hybrid system is described in Chapter 4. The antitumor efficacy of MNP-HFn in 
MFH therapies will be addressed in Chapter 5 in both in vitro and in vivo 
experiments. Chapter 6 describes a preliminary study on the drug carrier 
potential of MNP-HFn. In fact, we have verified the possibility of increasing its 
antitumor activity including a chemotherapeutic drug, doxorubicin, into the 
ferritin cavity. The analysis of the results obtained, the future perspectives and 
the issues to be overcome for utilization of MNP-HFn in clinic are presented in 
Chapter 7. Finally in Chapter 8, the experimental procedures and the 
instrumentation used in this work are described. 
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2. Synthesis and characterization of magnetite nanoparticles 
Nowadays, there is a great interest in the production of MNPs with magnetic 
properties tailored for biomedical applications, through reproducible, efficient 
and economically sustainable techniques. But even though the chemistry 
underlying the production of MNPs is virtually known, the critical dependence 
of their physical properties on the particle size, shape and structure, if on one 
hand allows for a fine tuning of their behaviour, on the other requires a tight 
control at the synthetic level. A wealth of methods of synthesis has been 
developed to answer to the different needs arising from the various applications 
meanwhile granting a fine control on the morphological properties. In the 
literature many procedures are described concerning the bottom-up approach 
and most of them are focused on the thermal decomposition of a precursor 
(metal-organic or inorganic salts) in the presence of surfactants in high boiling 
solvents1–3. It is worth to note that the thermal decomposition method is one of 
the best in terms of crystallinity, size distribution and magnetic properties of the 
final product, particularly if compared with the co-precipitation method, the sol-
gel processes or the synthesis in reverse micelles. Thanks to these advantages 
thermal decomposition has rapidly gained a large popularity, becoming one of 
the most common method for the production of MNPs4. However, despite of its 
large popularity, this technique is still suffering some drawbacks in terms of 
reproducibility and size or composition control. The main hurdle found by each 
"nanoparticle-chemist" is indeed to reproduce in his laboratory the procedure 
illustrated in a paper. This is mainly due to the great number of experimental 
variables that must be simultaneously controlled in the reaction set-up, like the 
temperature increasing rate, the stirring rate, the nitrogen flow and many others. 
Each one of them, indeed, affects the nature and the quality of the final product, 
thus it is essential to finely control all the synthesis parameters in order to obtain 
the desired product5.  
  20
In this work, the thermal decomposition of iron acetylacetonate has been 
chosen as the method to obtain good quality magnetite MNPs in the range of 12 − 16	34 exploitable for our purpose. 
In the next paragraph, the optimization of the MNP synthesis in order to obtain 
a material with the desired properties and with a good yield for the realization 
of all chemical-physical, magnetic and in vitro and in vivo tests, will be 
described, while in the following paragraphs we will report the synthesis and 
characterization of the MNP-HFn hybrid nano-system.  
 
2.1 Synthesis of magnetite nanoparticles 
Thermal decomposition of Iron(III) acetylacetonate (-.(6767)"), is a common 
route to prepare MNPs of magnetite with excellent structural and physical 
properties. Unfortunately, a major drawback is represented by the difficulty to 
obtain MNPs in the 12-16nm range which, as will be discussed in the next 
chapter, is the best for their use in hyperthermia. In an attempt to overcome this 
limit, we modified the thermal decomposition procedure of -.(6767)" described 
by Sun and Zeng3,6, changing the composition of the reaction mix and the 
heating ramp. In fact, in our synthesis the reaction mix was typically composed 
by an amount of -.(6767)", oleic acid (OA) and oleylamine (OAm), in molar 
proportion 1:5:5 (typically 8: 40: 40	44=>) mixed in c.a 100	4? of benzylether 
with a typical yield of ≈ 700	4B of dry powder of MNPs. Unlike the synthesis 
proposed by Sun and Zeng we did not use the 1,2 hexadecandiol (HDD), and 
we used a different heating ramp, as described in scheme 2.1, modulating C% 
and C$. The role of HDD is much discussed in the literature: some studies find 
that the absence of HDD does not influence the iron oxide stoichiometry, i.e. 
the Fe2+:Fe3+ ratio, but slightly reduces the size of the nanoparticles7. Therefore, 
also considering the high cost of HDD, we did not use it but we used the other 
synthetic parameters, as the volume of solvent, concentration of reagent and 
 
 
 21 
reaction time, to tune the characteristic of MNPs. Briefly, in a typical synthesis 
the mix was magnetically stirred for 30	4E3 under a flow of nitrogen at room 
temperature, then, once reduced the flux of nitrogen, it was heated to 200	°G in 15	4E3, kept at this temperature for some time, C% (nucleation), heated in 10	4E3 
to reflux, at c.a 295 °C, and kept there for C$ (growth). 
 
Scheme 2.1: Heating ramp for the synthesis of MNP by thermal decomposition of Fe(acac)3 ; the first step at C% and J% (200	°G in our case,), represented by the blue line corresponds to the nucleation of MNP seeds, the second step 
at C$ at the reflux of solvent J$  represent by the red line, corresponds the growth of the nuclei. 
 
Sample t1(min) t2(h) Volume (mL) 
MNP-1 30	 1	 125	
MNP-2 30	 1	 110	
MNP-3 30	 1,5	 110	
MNP-4 30	 1,5	 110	
MNP-5 30	 1,5	 100	
Table 2.1 Synthesis parameters used to produce MNPs. t
2
 and the volume of benzylether were changed to tune the 
size of the MNPs. 
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Several preliminary syntheses were initially performed varying the various 
parameters (t1, t2, T1 and T2), with the aim of investigating their effect on the 
morphological characteristics of the final product. These studies, not reported 
here, showed that keeping C% = 30	4E3 and J% = 200	°G and changing C$ and 
the volume of solvent, we were able to synthesize monodisperse MNP with 
controlled size in the range of interest. Indeed, using nucleation times C% longer 
than 30	4E3LC.M, independently of the value of the other parameters, we 
obtained MNPs of size lower than 10 nm, which is not suitable for application 
as heat mediator in MFH. At the same time, it is necessary reduce the solvent 
volume to increase the size to the desired ones. Indeed, at reflux the reaction 
mix is instable, and is hard to have the desired control over the T increasing C$ 
over 2	ℎ. Thus, a set of samples was prepared varying the solvent volume with C$ < 2	ℎ, and fixing C% = 30	4E3; the conditions used are reported in table 2.1. 
Samples MNP-4 and MNP-5 differ from previous samples in the cooling 
procedure of the reaction mixture. While MNP-1, -2, -3, were quenched to room 
temperature MNP-4 and MNP-5 were allowed to cool down spontaneously. 
This shrewdness has allowed us to produce MNPs with narrower size 
distribution. 
The analysis by the Rietveld method of the diffraction patterns of the dried 
powder confirmed that all the MNPs produced with this synthesis have the 
cubic spinel crystalline structure of magnetite (PDF 65-3107), Figure 2.1. The 
XRD data also evidence the absence of traces of wüstite or hematite, which, 
being antiferromagnetic, would have had a negative effect on the magnetic 
properties of the MNPs. The Pawley analysis method carried on the XRD 
patterns (Table 2.2)8, was used to estimate the size of the crystallite and the 
lattice parameter of the crystalline cell. Again, this analysis confirms the good 
quality of the samples as the lattice parameter 6 were extremely close to that 
of magnetite (6 = 8,3970Å) than to the maghemite one (6 = 8,3515Å). Indeed, 
magnetite is the desired iron oxide spinel phase, since it has a better 
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hyperthermic efficiency than maghemite. As it can be seen in table 2.2 the 
crystal sizes obtained from the Pawley method suggest that we were able to 
modulate the dimension of MNPs in the 9 − 15	34 range.  
 
Figure 2.1: XRD Patterns of samples MNP-1, MNP-2, MNP-3, MNP-4 and MNP-5. The red bars correspond to the 
reference pattern of magnetite (PDF 65-3107). 
Sample 
Crystal 
size (QR) Lattice Parameter Å S&'( (QR) S)* (QR) T)* 
MNP-1 9,3	 8,407(3) 8,0 ± 0,9	 8,0 ± 0,8	 0,102 
MNP-2 10,9	 8.401(0)	 10,6 ± 1,2	 10,8 ± 1,1	 0,101 
MNP-3 12,1	 8,396(3)	 13,5 ± 1,9	 13,7 ± 1,7	 0,125 
MNP-4 12,8	 8,391(1)	 12,7 ± 0,7	 12,7 ± 0,8	 0,065 
MNP-5 15,2	 8,398(1)	 15,8 ± 1,1	 15,8 ± 1,3	 0,079 
Table 2.2: Crystal size and lattice parameter obtained from the XDR patter fit with Pawley method using T.O.P.A.S.® 
software, for MNP-1, MNP-2, MNP-3, MNP-4 and MNP-5; Mean diameter from statistical analysis of the size 
measured on TEM micrograph; S+, Mean Diameter of Log Normal Fit, and W+,, standard deviation of the Log Normal 
equation. 
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For each sample electron micrographs were acquired with a Transmission 
Electron Microscope (TEM), to reveal the MNP size and evaluate the size 
distribution. Sample MNP-1 was characterized by a narrow population of, 
irregular, tiny MNPs, with mean diameter, X-./ = 8,0 ± 0,9	34, which is too 
small for deliver heat by magnetic fluid hyperthermia (Figure 2.2), while sample 
MNP-2 comprises bigger nanocrystals with average size X-./ = 10,6 ± 1,2	34, 
which, unlike the previous case have a more regular octahedral shape. 
 
Figure 2.2: A selected TEM micrograph of MNP-1, and the corresponding size distribution of diameter obtained by 
a statistic over several images; the average diameter is X-./ = 8,0 ± 0,9	34; the green thick line is the fitting to a log 
normal function with X+, = 8,0 ± 0,8	34. 
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Figure 2.3: A selected TEM micrograph of MNP-2, and the corresponding size distribution of diameter obtained by 
a statistic over several images; the average diameter is X-./ = 10,6 ± 1,2	34; the blue thick line is the fitting to a log 
normal function with X+, = 10,7 ± 1,1	34. 
The MNPS of samples obtained increasing C$, MNP-3-4-5 have a bigger 
average size, as shown in Figures 2.4, 2.5 and 2.6. In particular, MNP-3 
presented a broader size distribution centred at X-./ = 13,5 ± 1,9	3	4 with 
MNPs of octahedral shape. MNP-4 instead was composed by more uniform 
and smaller MNPs, with X-./ = 	12,7 ± 0,7	34, extremely regular in shape. 
MNP-5 was composed by MNPs larger in size, X-./ = 	15,8 ± 1,2	34 MNPs, 
which even in this case have a regular octahedral shape. As previously 
mentioned the different cooling procedure used in the synthesis of MNP-4 and 
MNP-5, had given narrower size distribution compared to MNP-3. 
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Figure 2.4: A selected TEM micrograph of MNP-3, and the corresponding size distribution of diameter obtained by 
a statistic over several images; the average diameter is X-./ = 13,5 ± 1,9	34; the black thick line is the fitting to a 
log normal function with X+, = 13,6 ± 1,7	34. 
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Figure 2.5: A selected TEM micrograph of MNP-1, and the corresponding size distribution of diameter obtained by 
a statistic over several images; the average diameter is X-./ = 12,7 ± 0,7	34; the purple thick line is the fitting to a 
log normal function with X+, = 12,7 ± 0,8	34. 
  28
 
Figure 2.6: A selected TEM micrograph of MNP-1, and the corresponding size distribution of diameter obtained by 
a statistic over several images; the average diameter is X-./ = 15,8 ± 1,1	34; the red thick line is the fitting to a log 
normal function with X+, = 15,8 ± 1,3	34. 
TEM micrographs and XRD data confirm that this procedure allowed us to 
obtain samples with high purity of the crystalline phase, and remarkable control 
over the size distribution. Among the samples we selected those which size falls 
in the range of our interest, 12 − 16	34. We can thus conclude that the 
experimental conditions used in this work for the synthesis of MNP-3, -4 and-
5, are suited to obtain magnetite MNPs which are efficient heat mediators for 
magnetic fluid hyperthermia.  
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2.2 Magnetic Characterization of magnetite nanoparticles 
 
Magnetic properties, clearly, define the ability of the MNPs for the 
nanomedicine applications of our interest. Therefore, the magnetization of the 
samples was deeply characterized both as a function of temperature and 
magnetic field. In particular, since particles with size below 11 nm have very low 
hyperthermic application in the following will be discussed only the properties 
of the most promising samples: MNP-3, MNP-4, MNP-5. 
All samples were firstly investigated by studying the temperature dependence 
of the magnetization recorded after zero-field cooling (ZFC) and field-cooling 
(FC) procedures; in Figure 2.7 are reported the ZFC-FC magnetizations of 
samples MNP-3, MNP-4 and MNP-5. The three ZFC-FC curves do not show 
the behaviour expected for not interacting single domain MNPs of size below 
15 nm. Actually, the dipole-dipole interactions master the variation of 
magnetization when this is measured on strongly interacting compact powders, 
producing an increase of the blocking temperature, J0, which, as it is our case, 
falls above the investigated temperature range. Remarkably, in all samples, 
around 100	Y it is visible a kink which can be ascribed to the Verwey transition, 
a transition typical of bulk magnetite occurring at 120	Y and due to a structural 
rearrangement, with a variation of crystal cell from orthorhombic at low 
temperature to cubic for temperature above 120	Y9. 
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Figure 2.7: Temperature dependence of the ZFC-FC magnetizations of: A) MNP-3(black line); B) MNP-4 (purple line); 
C) MNP-5 (red line). Empty and full dots refer to ZFC and FC magnetization, respectively. 
Figures 2.8 and 2.10 show the magnetization as a function of the applied field, 
at low temperature (2,5Y) and room temperature(300Y), respectively. At both 
temperatures the magnetization of all samples, was almost saturated at the 
highest measuring field of 5	J; indeed, the difference between the values 
measured at 5	J and those extrapolated from the fit of the high field data point 
to the empirical law Z	 =	Z1 + 6/\	 + ]/\$ is always lower than 1,2	%. Such a 
small difference indicates that the MNPs have a highly ordered magnetic 
structure, which, in turns reflects the high crystallinity and low defectivity 
evidence by XRD data. 
At low temperature the saturation magnetization, Z1 were for all the samples 
higher than 80	.4L/B; these value are close to the literature value of the 
corresponding bulk materials (95	.4L/B magnetite, and 82	.4L/B maghemite), 
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10 confirming the single crystal nature and the high crystallinity of the inorganic 
cores. 
In figure 2.9 are shown the enlargement of the low field region of the curves 
recorded at 2.5	Y. All samples show, as expected, an open hysteresis loop. The 
characteristic parameter of the hysteresis, coercive field \2 , and reduced 
remnant magnetization Z3-/Z4- are reported with the Z1 values in table 2.3 
 
 
Figure 2.8: Hysteresis loop recorded at 2,5	Y. A) MNP-3 (black symbols); B) MNP-4 (purple circles); C) MNP-5 (red 
circles). 
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Figure 2.9: Details of the hysteresis loop in the low field region. A) MNP-3 (black symbols); B) MNP-4 (purple 
symbols); C) MNP-5 (red symbols). 
 
The coercive fields, \2 , are slightly lower with respect to the value reported in 
the literature for MNP of magnetite of these dimension11, indicating that 
magnetic anisotropy, K, is not very high. An approximate estimate of the 
anisotropy constant can be obtained assuming the coercive field at low 
temperature is equal to the anisotropy field, HAn, i.e. \2 = \56 = 2_/`3Z1. 
Under this assumption we obtained for our samples _ = 1,05 ∙ 104	.aB/74"cm 
for MNP-3, _ = 1,20 ∙ 104	.aB/74"for MNP-4, and _ = 1,34 ∙ 104	.aB/74"for 
MNP-5. These value are rather lower than the term of magneto-crystalline 
anisotropy of maghemite and magnetite12. However, it should be taken into 
account that _ values obtained in this way could be underestimated due to the 
reduction of the effective field for the reversal of the magnetization caused by 
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inter-particles interactions, which, as we had seen before, are extremely 
relevant in powder samples.  
Sample 
b7	cdde 
(fRg/h) b7i,je (fRg/h) k8 (lf)	 b9&/b:&	
MNP-3 72 81 237 0,41 
MNP-4 74 83 265 0,35 
MNP-5 78 89 273 0,42 
Table 2.3: Magnetic saturation, Z1 extrapolated from magnetization curves at room temperature (300 K) ad low 
temperature(2,5 K); Coercive Field, \2, and remnant magnetization Z3-/Z4- obtained from the hysteresis loop. Z1 
were given as emu per g of magnetc material. 
 
In the room temperature loops, no magnetic irreversibility is observed, as shown 
in Figure 2.11, indicating on this time scale, the MNPS are in the 
superparamagnetic state for all the samples, as expected for magnetite MNPs 
of this dimension. The saturation magnetization calculated from the fit of the 
high field data are reported in table 2.3. 
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Figure 2.10: Magnetization recorded at room temperature. A) MNP-3 (black line); B) MNP-4 (purple line); C) MNP-5 
(red line). 
 
Figure 2.11: Details of the magnetization recorded at room temperature in the low field region. A) MNP-3 (black 
circles); B) MNP-4 (purple circles); C) MNP-5 (red circles). 
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2.3 Functionalization of MNPs with hydrophilic ligand 
The synthesized MNPs are covered by a layer of Oleic Acid (OA) which makes 
them soluble in apolar solvents. As a pre requisite, for their subsequent 
functionalization with ferritins, it is necessary to replace the surfactant with a 
ligand that allows the dispersion in water and exposes on the surface functional 
groups suitable for the following grafting of the protein. The strategy adopted 
was based on the ligand exchange, i.e. treating a MNP suspension with a high 
excess of a bifunctional molecules containing at one end a functional group 
with high affinity for the surface of the inorganic nucleus and at the other a 
functional group suitable for the linkage of HFn. To this purpose, we chose 3-
AminoPropylPhosphonic Acid (APPA). This ligand has high affinity for iron 
oxide, conferred by the phosphonate group forming stable covalent bonds on 
the surface of the MNP13. In addition, it possesses a primary amine (-NH2) that 
ensures the necessary hydrophilicity, and at the same time it is available for 
subsequent functionalization with HFn. Indeed, amino groups can easily react 
with activated acyl groups forming an amide, a reaction which has been 
exploited n our case, to connect the MNP with an ethero-bifunctional linker. as 
will be described later. 
The toluene suspension of MNPs (10mg/mL Fe3O4) was mixed with an equal 
volume of a dichloromethane solution of APPA (10mg/mL) and 
Tetramethylammonium hydroxide (TMAOH, 10mg/mL) and sonicated for one 
hour. Then, MNPs were separated with a permanent magnet, washed with 
ethanol and suspended in water. 
After the reaction the samples appear as a limpid, dark brown water 
suspension, which remains stable over long time, usually at least 6 months. The 
high hydrophilicity of the product, nicely suggests the complete realization of 
the ligand exchange, which was further also confirmed by CHN analysis and by 
the Z-potential values ≈ −24	4m of the water suspensions.  
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The magnetic properties of the MNPs were controlled after the ligand exchange 
with APPA, in order to verify if the coordination modification of the iron ions 
located at the surface could affect the behaviour of the core. 
From the field dependence of the magnetization at low (2.5 K) and room 
temperature, shown in figures 2.12, 2.13, and 2.14, for MNP-3, MNP-4 and 
MNP-5, respectively; we can note that in all cases the saturation magnetizations 
does not change, although a clear variation in the approach to saturation is 
observed. Indeed. After the ligand exchange the MNPs require a larger field to 
saturate. Moreover, after coating with APPA an increase of the coercivity from 
about 250 to about 500 is observed. For the sake of clarity, the values of the 
main magnetic parameters extracted from these curves are summarized in 
Table 2.4. 
 
 
Figure 2.12: Field dependence of the magnetization for MNP-3 (black circles) and MNP-3@APPA (red circles) 
recorded at: A) room temperature; B) low temperature; C) detail of the low field region. 
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Figure 2.13: Field dependence of the magnetization for MNP-4 (black circles) and MNP-4@APPA (red circles) 
recorded at: A) room temperature; B) low temperature; C) detail of the low field region. 
 
Figure 2.14: Field dependence of the magnetization for MNP-5 (black circles) and MNP-5@APPA (red circles) 
recorded at: A) room temperature; B) low temperature; C) detail of the low field region. 
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 MNP-3 MNP-3 @APPA MNP-4 
MNP-4 
@APPA MNP-5	 MNP-5 @APPA	b7	cdde 
(fRg/h) 72 75 74 74 78 79 b7	i, je 
(fRg/h) 81 83 83 86 89 91 k8 (lf) 237 525 265 500 273 480 b9&/b:& 0,41 0,42 0,35 0,41 0,45 0,45 
Table 2.4: Magnetic parameters of samples before and after the ligand exchange. Magnetization saturation, Z1 was 
extrapolated from the high field data; Coercive Field, \2, and remnant magnetization Z3-/Z4- obtained from the 
hysteresis loop. Z1 were given as emu per g of magnetc material. 
 
The variation of these parameters is coherent with an increase in spin disorder 
at the surface occurred after the change of functionalization. The coordination 
of the carboxyl group of OA to the surface metal ions is known to reduce the 
surface spin disorder14. On the other hand, the coordination of the phosphonate 
of APPA may produce a lower degree of spin alignment at the surface 
increasing the spin disorder which often characterize small MNPs. The 
increased spin disorder reverberates on the magnetic properties of the MNPs 
on two levels, on the one hand it makes the saturation more difficult, on the 
other hand, it makes larger the energy barrier to be overcome to reverse the 
magnetization, causing an increase in the coercive field.  
In this Chapter we have seen how the thermal decomposition synthesis can be 
successfully used to prepare MNPs of controlled size by simply tuning some 
synthesis parameters, such as C$ times and the reaction volumes. The analyses 
performed confirmed that all the samples contain only one crystalline phase, 
with no defects, exhibit superparamagnetic behaviour at room temperature and 
bulk-like magnetic saturation. In conclusion, we can claim that the chosen 
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synthesis permitted to produce inorganic magnetic cores with characteristic 
suitable for the realization of a nano-device for biomedical applications. 
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3. Magnetic properties applied to nanomedicine 
 
As previously described the main goal of this work is to exploit the properties 
of MNPs with superparamagnetic behaviour for both therapeutic and diagnostic 
applications. In this chapter, after a brief introduction on the mechanisms 
responsible for the heating capability of MNPs, we will discuss the efficiency in 
magnetic hyperthermia and magnetic resonance imaging of the MNPs and 
MNP-HFn systems prepared in this work. 
 
3.1 Magnetic Hyperthermia 
3.1.1 MNPs heat releasing: mechanism and efficiency 
 
The heating efficiency of a given material under the application of an alternating 
magnetic field, is quantified by the Specific Absorption Rate (SAR), defined as 
the amount of energy converted into heat per unit of time and mass. The main 
mechanisms responsible for the heat dissipation process are: 
• the development of parasitic currents (eddy currents); 
• The irreversible reversal of the magnetization, (hysteresis cycle). 
For particles in the nanometric scale, the first contribution can be neglected 
because the size is are too small for eddy currents to be induced. 
When a magnetic field of frequency n and amplitude \3is applied to a dispersion 
of MNPs in water, the amount of magnetic energy converted into heat is 
proportional to the hysteresis cycle area: nop = `3n∮Z(\)X\     (1) 
where `3 is the magnetic permeability of free space. 
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To assess the cycle area and to describe the mechanism by which heat is 
developed, we can adopt different models, whose applicability depends on the 
size of the MNPs. For mono-dispersed MNPs, the heat development 
mechanism can be described by the linear response theory (LRT). The main 
assumption of this model is that the magnetization varies linearly with the 
oscillating magnetic field: \(C) = \3 7=M 2rsC = p;\3.<$=>?    (2) 
so that Z(C) = t ∙ \(C) = t ∙ p;\3.<$=>? = \3(t@ 7=M 2rsC + t@@ ME3 2rsC) (3) 
Where C is the time of oscillation of the AMF and t’ and t’’ represent the in-
phase and out-of-phase part of the magnetic susceptibility, respectively. This 
hypothesis is valid if we assume that the magnetic anisotropy barrier and the 
field oscillations are small compared to thermal energy, Ym _0Jv ≪ 1 and `3	`\ _0Jv ≪ 1; where Y is the anisotropy constant, m is the volume of the MNP, _0 is the Boltzmann costant, ` the magnetic moment and, \ the external 
magnetic field. When these conditions are met, the dissipated power is given 
by: nop = =nABCBDE · c@@ = =nABDCBD/FDG"EHI- · $=ntJKK%L($=ntJKK)D   (4) 
where y is the density of the material, and z;OO is the effective relaxation time 
of the magnetization. Considering a MNP system suspended in a fluid matrix, 
then z;OO is due to two competing mechanisms: Néel relaxation, described as z, = z3. PQRIS, which depends on the intrinsic magnetic characteristics of MNPs 
and Brown relaxation, z0 = "TGUHI- , corresponding to the physical rotation of 
MNPs in the fluid in which they are suspended. Brown's relaxation therefore 
depends on the hydrodynamic characteristics of the fluid as the viscosity, { and 
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the hydrodynamic volume mC of the MNPs. Then z;OO will be determined by the 
fastest process: %VJKK =	 %VW + %VI      (5) 
From Eq. 4 two main considerations follow. The first is that maximization of the 
SAR occurs when 2rntXYY 	 = 	wtXYY 	= 	1, namely when the relaxation time is 
equal to the characteristic time of the measurement (in this case the inverse of 
the applied field frequency). These condition corresponds to the blocking of 
magnetization at the times scale of the experiment. Secondly, for in vivo 
application of hyperthermia, it is always better to have Néel relaxation as a 
dominant process. In fact, in this way, the dissipated power depends solely on 
the intrinsic properties of the inorganic nucleus (size and anisotropy), and 
remains independent of environmental conditions that are not always easily 
controllable.  
From eq. 4 it is even clear that many parameters influence the heat power 
dissipation. In figure 3.1 is represented the SAR dependence on the 
magnetization of saturation, on the anisotropy and on the dimension evaluated 
using Eq. 4. Figure 3.1A shows that for magnetite MNPs (Y = 15	_|4Z", M[ =450	Yo4Z%) the SAR has a well pronounced, sharp maximum at a definite value, 
arising from the sum of the contribution of Néel and Brown relaxation. Figure 
3.1b and 3.1c demonstrate that the maximum of SAR grows as the 
magnetization saturation increases and as the crystalline energy decreases, 
and, in the latter case, it shift to lower diameters. 
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Figure 3. 1 Dependence of SAR evaluated from Eq. 4 on A) Size, B) magnetization saturation and C) magnetic 
anysotropy (crystalline energy). All the calculation were performed for a magnetite MNPs, Y = 15	_|4Z", Z1 =450	Yo4Z%, \3 = 10_o4Z%and ~ = 500_\z. 
 
Typically for MNPs of magnetite the dimension that maxime SAR according to 
theoretical evaluation fall in the 12 − 18	34 windowrange, and in 15 − 2334 
range for maghemite1. However, for a real system, we should always consider 
the polydispersity of the sample. Size distribution of MNPs can be usually 
described by a log-normal distribution function: 
~(X) = Ä\WÅ√ÉÑ · .ÖÜ á− (àâ	(Å Å\W))⁄ DÉÄ\WD ã    (6) 
where	ln	 X?é is the expectation value of the log-normal distribution and Wèê is 
the standard deviation of >3(X). Then the SAR of the polydispersed sample 
becomes: nop?]? = ∫ =>ABCBDE ∙ t@@3^ ∙ ~(X)	dX    (7)  
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Figure 3. 2 Variation of SAR as a function of ωτ, for MNPs distributions with X	 = 	1234 and W+, 	= 0/0,1/0,05/0,001. 
B) Distribution Functions Used to Calculate SAR with Eq. 6. 
In Figure 3.2, left panel, the variation of SAR as a function of íz for the size 
distribution reported in the right panel, are shown. The Figures show that proper 
size and narrow dimensional distribution are the fundamental requirements to 
maximize heat dispersion efficiency for a given material. 
 
3.1.2 Heating power, limits and evaluation 
As mentioned in the previous paragraph, SAR depends directly on the square 
of the applied field amplitude, \3, and on the operating frequency s. Taking a 
sample of MNPs it might be thought that the simplest way to increase SAR is 
to increase the parameters of the applied AMF. However, only a narrow window 
of \3 and s are allowed for in-vivo application. Figure 3.3 shows AMF exposure 
limit values, obtained from theoretical evaluations, beyond which eddy currents 
are generated in the tissues, and peripheral nerves and heart tissue are 
stimulated2. The grey area between the dotted lines represents the safety area 
in terms of frequency and strength in which it is possible to operate without 
major side effects. These values, obtained by theoretical modelling2,3 have not 
been experimentally verified on human being, yet. In the Figure are reported 
also the field values used in clinical trials carried out by Jordan et al4,5, (red 
arrow), which partially exceed the theoretical limit. As a matter of fact, in the 
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absence of a thorough clinical study on safety limits and regulations about 
human body exposure to AMF, currently are considered as safe operating 
condition in which	\3 × s does not exceed 5 ∙ 10_	o4Z%MZ%. This values have 
been obtained by monitoring side effects on humans directly exposed to the 
AMF. Based on this limit, the commonly accepted field parameters are \3 ,	below18	_o4Z% and frequencies between 100 − 300	_\î. 
 
Figure 3. 3: Stimulus thresholds of peripheral nerves and heart tissue under the action of an AMF for an average adult. 
The dotted line represents the threshold for cardiac tissues, the dot-dashed line the peripheral nerves while the 
dashed line the threshold beyond which eddy current are generated. Red arrow represents experimental conditions 
in MFH trials; the violet star corresponds to the value used for the most of experiments performed in this work. 
In all the experiments carried out in this experimental work we chose an AMF 
of 17	_o4Z%and 183	_\î, below the above mentioned threshold. 
The simplest way to experimentally evaluate the SAR is to perform a 
calorimetric measurement of MNPs suspended in a fluid and exposed to an 
AMF. The SAR can in fact be obtained by measuring the total heat released by 
the system divided by the mass of the heating material and the time of action 
of the AMF: 
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nop = ∑ ñóòôóóñöõ ∙ △ù△û 	(üB†)    (8) 
where ∑ 4<G`<< △ J is the sum of the amount of heat released by all the 
components E of the system, 4/; is the total mass of the magnetic material and △ C is the time of action of the AMF.  
Experimentally, the SAR evaluation is performed by measuring the temperature 
variation during the AMF application under adiabatic conditions, from which △ù△û  
is obtained; then, if the composition of the system is known the SAR can be 
calculated through Eq. 8. If the measuring system were perfectly adiabatic, the 
variation of temperature during the time of measurement would be linear, and 
the SAR could be simply calculated from the final △ù△û . However, most of the 
measuring devices are not perfectly adiabatic and the temperature kinetics are 
therefore affected by the heat exchange of the sample with the environment. 
Due to this instrumental limit, the most commonly procedure consists in 
extrapolating the initial slope of the curve	J(C), to obtain a ÅùÅû  value where the 
heat dissipation is minimal. Figure 3.4 shows a typical elaboration of the 
experimental data, with the linear fit of the temperature kinetic of a sample of 
MNPs exposed to an AMF. 
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Figure 3. 4: Example of the elaboration of the kinetic evolution of temperature to extrapolete the initial slope. Black 
line is the experimental data, red line the linear fit of °C = 15	M, dotted line the evolution of an adiabatic system 
 
3.1.3 Hyperthermic efficiency analysis 
 
As mentioned in Chapter 2, samples with most suitable dimension for 
biomedical applications are MNP-3-4-5. Here we analyse and discuss the 
hyperthermic behaviour of these three samples. The hyperthermic properties 
were measured suspending the MNP in different media: toluene, water and 
agarose gel. Such an in-depth study of the hyperthermic behaviour of MNPs is 
aimed at verifying that the hyperthermic efficiency is not adversely affected by 
the environment in which they are suspended. Indeed, as previously mentioned, 
SAR is influenced by both intrinsic and external parameters, whose a priori 
evaluation from magnetic data is not simple. 
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3.1.3.1 Hyperthermic efficiency in organic suspension 
 
To investigate the hyperthermic efficiency of toluene suspension of the three 
MNP samples coated with oleic acid, aliquots of 1mL at a concentration of 5	4B/4? of each samples were exposed to a AMF of 183	_\î frequency and 17	_o4Z% amplitude, while recording the temperature variation during the time 
of the action of the field by a optic fiber probe dipped into the sample. 
The temperature increase was evaluated by a linear fit of the initial slope, as 
previously described, taking at least 10	M as °C. For every sample many different 
measurements were repeated to verify the reproducibility of the experiment. In 
figure 3.5 are shown the heating kinetics of MNP-3, MNP-4 and MNP-5. 
 
Figure 3. 5: kinetic evolution of temperature of 5	4B/4? toluene suspension of MNPs. MNP-3, black line; MNP-4, 
red line; MNP-5, green line. 
The SAR evaluated for the samples are reported in table 3.1. Sample MNP-5 
(15,8	34) shown as expected, the highest value, 81,2	üBZ%, while MNP-4 
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(12,7	34) and MNP-3 (13,5	34), although of comparable size display significant 
different SAR. 
Sample ¢£§	(•h(*aZb ) b¶ß− c 33,5 b¶ß− ® 55,8 b¶ß− j 81,2 
Table 3. 1 SAR values obtained for MNPs suspension in toluene, 5	4B/4? of concentration of iron oxide, applied 
field of 183	_\î frequency and 17	_o4Z%	intensity for °C = 	300M. 
 
3.1.3.2 Hyperthermic efficiency in water suspension 
 
The value of SAR measured in toluene is not necessary representative of the 
intrinsic SAR of the sample. Indeed, MNPs suspended in different media can 
experience different interactions and can also have different stability, two 
factors which can influence the final heating efficiency. 
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Figure 3. 6: Kinetic evolution of temperature of a MNP-3 water suspension with increasing concentration 1, 2,5, 5	63X	10	4B/4?. 
The hyperthermic efficiency of water dispersion of MNPs samples was 
investigated after the ligand exchange with APPA. Aliquots of MNPs suspension 
with different concentration in the range 10	4B/4?	– 1	4B/4? were exposed 
to an AMF using the same field parameters. In Figure 3.6 the kinetic curves 
recorded for MNP-3 are shown. As expected the SAR values reported in table 
3.2, are almost double compared to the ones evaluated in toluene. 
b¶ß− c ¢£§	(•h(*aZb ) ™dRh/R´ 65,8 ± 5,1 jRh/R´ 58,3 ± 4,7 i, jRh/R´ 69,0 ± 6,0 ™Rh/R´ 58,6 ± 4,1 
Table 3. 2 SAR values obtained for MNP-3 sample suspended at different concentration in 1	4? of water and 
exposed for 300	M to a AMF (183	_\î, 17	_o4Z%); mean values are obtained averaging over 5 data. 
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Even in water suspension SAR is independent on the concentration, the 
observed oscillations being within the uncertainty of measurement. Comparing 
curves recorded in water and toluene suspensions at same concentration (5 
mg/mL) the total ∆T is larger in toluene due to the much higher specific heat of 
water.  
Interestingly, SAR value for MNP-4 and MNP-5 were closer each other and 
significantly much higher than MNP-3. In figure 3.7 are shown the kinetic curves 
recorded for sample MNP-4 at different concentration while in table 3.3 are 
reported the mean SAR evaluated at each concentration. 
 
Figure 3. 7: Kinetic evolution of temperature of a MNP-4 water suspension with increasing concentration 1, 2,5, 5	63X	10	4B/4?. 
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b¶ß− ® ¢£§	(•h(*aZb ) ™dRh/R´ 146,8 ± 5,5 jRh/R´ 148,5 ± 8,5 i, jRh/R´ 152,1 ± 8,6 ™, iRh/R´ 139,9 ± 4,8 
Table 3. 3 SAR values obtained for MNP-4 sample suspended at different concentration in 1	4? of water and 
exposed for 300	M to a AMF (183	_\î, 17	_o4Z%); mean values are obtained averaging over 5 data. 
It deserves to be mentioned that MNP-4 has a SAR more than double than 
MNP-3, a results which confirms the theoretical model discussed above, for 
which MNPs of same dimension but narrower distribution posses higher SAR. 
In this case, indeed, MNP-3 and MNP-4 had similar size ≈13nm but slightly 
different skewness 0,12 and 0,06, respectively, which, as demonstrated figure 
3.1 A by the comparison of the 0,05 and 0,01 curves, should produces a 
difference in SAR comparable to that observed in our case. 
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Figure 3. 8: Kinetic evolution of temperature of a MNP-5 water suspension with increasing concentration 
(1, 2,5, 5	63X10	4B/4?). 
MNP-5 exhibits the highest SAR among the three samples, 158,6 ± 4,2W/g. 
This result can be ascribed to its higher diameter. In Figure 3.8 are displayed 
the curves recorded as a function of the concentration, while in table 3.4 the 
mean value of SAR evaluated at different concentrations are reported. 
b¶ß− j ¢£§	(•h(*aZb ) ™dRh/R´ 157,6 ± 1,7 jRh/R´ 157,3 ± 3,9 i, jRh/R´ 161,7 ± 5,1 ™, iRh/R´ 158,2 ± 5,1 
Table 3. 4 SAR values obtained for a MNP-5 sample suspended at different concentration in 1	4? of water and 
exposed for 300	M to a AMF (183	_\î, 17	_o4Z%); mean values are obtained averaging over 5 data. 
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In figure 3.9 is shown a comparison of suspensions of the 3 samples at the 
same concentration (5	4B/4>) to better appreciate their different hyperthermic 
efficiency.  
 
Figure 3. 9: Kinetic evolution of temperature of a 5	4B/4? water suspension of MNPs. MNP-3, black line; MNP-4, 
red line; MNP-5, green line.  
All samples show good SAR values, comparable with those reported in the 
literature for MNPs used in nanomedicine applications6,7. A better comparison 
with data reported in the literature can be obtained by evaluating the Intrinsic 
Loss Power (ILP). The ILP parameter is simply the SAR parameter normalized 
to \$~ and it can be easily derived from heat loss data as Æ?Ø = nop \$~⁄  
(3\4$_BZ%)3,8. 
In table 3.5 are reported the ILP values of the three samples at 5	4B/4>. They 
are among the highest ILP values reported in the literature for magnetite MNPs 
of this size range, as well demonstrated by the comparison with experimental 
data reported in the literature and theoretical estimation, shown in Figure 3.103. 
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Sample ∞´ß	(QkRc±hZb) b¶ß− c 1,7 b¶ß− ® 3,7 b¶ß− j 4,0 
Table 3. 5: ILP values of MNPs calculated normalizing SAR values (W/kg of Iron) by \$~;\ = 17_o4Z% and~ =183_\î. 
 
Figure 3. 10: Comparison between theoretical predictions and experimental data on the size-dependent heating 
efficacy of magnetic fluids, expressed in terms of the intrinsic loss parameter, ILP (3\4$/_B of Iron). Image taken 
from Pankhurst et al. 3 
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3.1.3.3 Hyperthermic efficiency in agarose gel 
For MNPs that have to be used for in vivo MFH application it is mandatory that 
hyperthermic properties do not change when they arrive in situ inside the 
tissues and cells. Therefore, as previously mentioned, the reversal of 
magnetization should be a process mainly governed by Néel relaxation, and 
should not be affected by environment variables as it would be the case if 
Brownian relaxation would be the dominant one. To investigate the two 
relaxation processes separately, we studied the hyperthermic properties of 
MNPs suspended in agarose gel. By varying the percentage w/w of agarose 
from 0,0% to 4%, we can shift from a medium where the particle are free to 
rotate (water) to a completely blocked system. At very low percentage (0.25%) 
the agarose polymer forms a gel which mimes soft tissue, at higher percentage 
the gel has a density and stiffness similar to human tissues, while around 5% to 
bones and cartilages.  
We choose to suspend the samples in the agarose gel at a concentration that 
induce significant increase of T, thus reducing the error on SAR evaluation, but 
that at same time does not overcome the gelling temperature of the agarose gel (≈ 40 − 52°G). This corresponded to 3	4B/4? of magnetic core for MNP-3, 
while for MNP-4 and MNP-5 to 1	4B/4?. The kinetic curves recorded for the 
agarose samples of MNP-3 are shown in Figure 3.11. They reveal that only at 
the higher agarose percentage there is a significant change in the hyperthermic 
efficiency of the MNPs.  
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Figure 3. 11: kinetic evolution of temperature of a dispersion of MNP-3 in gel (3 mg/mL), varying the agarose 
percentage: % = 0 − 	0,25 − 	0,5 − 1 − 	3,3	63X	4. 
In table 3.6, are reported the mean values of SAR obtained for each samples 
compared to the ones obtained for the water suspension. Except for the 4% 
sample, all the others have similar SAR, within the uncertainty of the evaluation. 
In this case we can conclude that the reversal of the magnetization was mainly 
not affected by the gel environment at least at concentration lower than 4%. 
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b¶ß− c	£h≤≥ ¢£§	(•h(*aZb ) d% 62,9 ± 6,1 d, ij% 54,7 ± 4,8 d, jd% 60,2 ± 5,4 ™% 59,9 ± 6,2 c,c% 55,4 ± 1,4 ®% 34,6 ± 2,2 
Table 3. 6: SAR of a a dispersion of MNP-3 in agarose gel (3 mg/mL) at different concentration and exposed for 300	M to an AMF (183	_\î, 17	_o4Z%); mean values are obtained averaging over 5 data. 
Same considerations can be drawn from the kinetic curves of sample MNP-4 in 
agarose gel, shown in figure 3.12. In this case in fact the initial slope for all the 
sample, and accordingly the SAR values, are the same. However, unlike MNP-
3samples, the evolution of temperature changes among the various samples 
after 60 s of AMF action. Probably, this behaviour is an experimental artefact 
and can be ascribed to a different positioning of the optic fiber probe inside the 
volume gel. 
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Figure 3. 12: kinetic evolution of temperature of a dispersion of MNP-4 in gel (1 mg/mL), varying the agarose 
percentage% = 0 − 	0,25 − 	0,5 − 1 − 	2	63X	4 
In Table 3.7, is reported the SAR for MNP-4. Again, SAR values are almost the 
same for all the agarose gel concentrations. Also for this sample the heat 
efficiency does not vary when the MNPs were blocked in the gel, being 
hypothesized that a Néel relaxation drives the reversal of the magnetization. 
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b¶ß− ®	£h≤≥ ¢£§	(•h(*aZb ) d% 148,6 ± 4,2 d, ij% 135,5 ± 7,5 d, jd% 140,9 ± 3,3 ™% 141,7 ± 4,5 i% 147,1 ± 3,6 ®% 132,2 ± 6,6 
Table 3. 7: SAR values obtained for MNP-4 dispersed in agarose gel (1 mg/mL) at different concentrations and 
exposed for 300	M to an AMF (183	_\î, 17	_o4Z%); mean values are obtained averaging over 5 data. 
 
Last sample, MNP-5, differs from the previous two, as shown in figure 3.13, 
where the temperature kinetic curves at different concentration are shown. All 
the samples in gel have an initial slope significantly reduced compared to that 
recorded in water at the same concentration. All samples where MNPs are 
mechanically blocked show a similar behaviour, with no evident dependence 
on the percentage of agarose used. 
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Figure 3. 13: kinetic evolution of temperature of a dispersion of MNP-5 in gel (1 mg/mL), varying the agarose 
percentage % = 0 − 	0,25 − 	0,5 − 1 − 	3,3	63X	4 
Accordingly, the SAR of gel dispersions, reported in Table 3.8, are dramatically 
reduced, by a factor seven, revealing that for MNP-5 the reversal of 
magnetization in water is dominated by a Brownian relaxation process. This 
process is indeed hampered by the gel, thus reducing the efficiency of heat 
release when MNPs are embedded in this medium. 
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b¶ß− j	£h≤≥ ¢£§	(•h(*aZb ) d% 154,7 ± 7,7 d, ij% 24,5 ± 1,8 d, jd% 26,6 ± 3,8 ™% 22,7 ± 3,4 i% 17,2 ± 1,4 j% 20,7 ± 2,3 
Table 3. 8 SAR values obtained for MNP-5 dispersed in agarose gel (1 mg/mL) at different concentrations and 
exposed for 300	M to a AMF (183	_\î, 17	_o4Z%); mean values are obtained averaging over 5 data. 
In Figure 3.14 are plotted the SAR for all the samples against the percentages 
of agarose used, making the different behaviour in agarose gel more explicit. 
This result is crucial since in the final in vivo application the MNPs will be 
embedded in a strongly viscous environment where no mechanical rotation is 
allowed. Therefore, although MNP-5 possesses the best hyperthermic 
efficiency in water suspension MNP-3 and MNP-4 more suited for the 
functionalization with HFn. 
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Figure 3. 14: Dependence of SAR on the % of agarose. MNP-3, black symbols; MNP-4, red symbols; MNP-5, green 
symbols. 
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3.2 Magnetic Resonance Imaging 
 
3.2.1 Basic principle of Magnetic Resonance Imaging 
In a typical Magnetic Resonance Imaging, MRI, experiment the recovery of the 
magnetization of water 1H nuclei to its equilibrium value, after a perturbation, is 
used to map the anatomy and physiological process of the body. In a typical 
NMR experiment a stationary field, ¥3, is applied along the direction z, so that 
the nuclear magnetic moments will precess along the field direction. The 
macroscopic effect is a non-zero magnetization along z, as the resultant of the 
sum of the two populations of spins oriented along the two opposing 
orientations, as shown in Figure 3.15. 
 
Figure 3. 15: Orientation of a set of spins along the direction of the field, z. The spins rotate at the Larmor frequency í+. At the equilibrium, the vector sum of nuclear magnetic moments of protons result in a net magnetization of the 
sample along the z axis, with b	 = bd and be 	= 	bf 	 = 	d 
Therefore, a set of protons, with nuclear gyromagnetic ratio µ6 = 2,67 ∙10g	a6XMZ%JZ%, in a field ¥3 = 1	J oscillates with precession motion at 
frequency s3 = í+	/	2r = 42,57	Z\î. To perturb this system it is necessary to 
apply an electromagnetic pulse, usually a radiofrequency pulse, perpendicular 
to ¥3 oscillating at the same frequency of proton Larmor precession, s3. By 
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means of characteristic sequences of radiofrequency pulse, a coherent rotation 
of the nuclear spins is induced with the rotation of the magnetization in the plane 
and the vanishing of the magnetization along z (r/2 impulse). 
When the perturbation is switched off, the system spontaneously recovers the 
initial equilibrium. The recovery of magnetization along î and the decay in the Ö∂ plane are described by the Bloch equations (Figure 3.16): 
Zh(C) = Z3(1 − .Z iSj)     (9) Zk,m(C) = Z3(.Z iSD)     (10) 
 
 
Figure 3. 16: Temporal evolution of the magnetization along the z direction and in the xy plane after a 90° pulse 
has been applied. 
The temporal evolution of the magnetization in î and Ö∂ is described by two 
distinct characteristic relaxation times, J% and J$. J%, called spin-lattice 
relaxation time or longitudinal relaxation time, measures how the magnetization Zh comes back to the initial value Z3 and depends on the energy exchange 
between the spin system and the lattice. When magnetization recovers along î, 
magnetization in Ö∂ plane decays and the evolution of Zkm  is described by the 
characteristic time J$, called spin-spin relaxation time or transverse relaxation 
time. The relaxation in the Ö∂ plane can be faster than the recovery of Zh and 
is driven by phase coherence loss in the proton precession motions due to 
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magnetic interactions with other protons or with fluctuating magnetic fields 
generated in their environment (Figure 3.17). 
 
 
Figure 3. 17: Dephasing of spin after the application of the 90° pulse. The resultant magnetization decreases 
progressively as the system relaxes, restoring the equilibrium conditions 
Actually, signal decay occurs with a characteristic time that may be different 
from J$ and is generally indicted as JÉ∗. 
 
1TÉ∗ = 1TÉ + g ΔB∫2    
where °¥∫ includes inhomogeneity of the applied field ¥∫, and local variations 
of the system magnetic susceptibility. 
MRI relies on the fact that proton of water molecules in different environment 
have different relaxation time, to reconstruct a map of the body. The natural 
contrast can be further enhanced by using exogenous substance, the so-called 
contrast agents (CAs). Indeed, the presence of magnetic centres dispersed in 
water creates local field inhomogeneity which modify the relaxation process of 
water protons. Either MNPs or paramagnetic metals can be used as CAs, as 
they are able to significantly shorten J% and J$, respectively.  
The efficacy of a CA to enhance the contrast is quantified by the relaxivity, 
defined as the increase of the nuclear relaxation rate of a solvent, water in our 
case, induced by a concentration 1	4Z of a magnetic centre dispersed in it. 
The relaxivity is expressed in MZ%4ZZ%, and it is obtained by the formula: 
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 rº = 1c æ 1Tºø¿¡¬ − 1Tºnop√  
where E	 = 1, 2 indicates longitudinal relaxation or transverse relaxation, J<q;rs 
is the relaxation time measured for the sample with the paramagnetic or 
superparamagnetic agents, J<tuQ is the relaxation time of the diamagnetic host 
solution and 7 is the 4Z concentration of the magnetic centres. 
 
3.2.2 Analysis of the relaxometric properties of the inorganic cores 
The ability of MNP-3 and MNP-4 samples to increase the transverse and 
longitudinal relaxation of water protons was studied by measuring the Nuclear 
Magnetic Resonance Dispersion (1H-NMRD). The measurements were 
performed in the frequency range 0.01	Z\î ≤ ~ ≤ 60	Z\î.	The iron 
concentration of the suspension was evaluated by ICP and found 0.4	4Z and 0.6	4Z for MNP-3 and MNP-4 respectively. For each measured frequency the 
samples were previously sonicated to disperse any aggregate eventually 
formed. The relaxation rates a% and a$ of the two suspensions were normalized 
for the respective concentrations.  
In Figure 3.18 are shown the longitudinal relaxivity 1H-NMRD profiles of the two 
suspensions. In principle, several information can be extracted from these 
curves. In figure 3.19 it is shown a typical longitudinal 1H-NMRD relaxation 
curve for an assembly of small (i.e. X	 = 	5	34) superparamagnetic MNPs which 
is well described by the Roche model9. In general, the absence or the presence 
of a dispersion at low field provides information on the magnetic anisotropy of 
the system. If a low-field dispersion is present, the particle's anisotropy energy 
is low and therefore its magnetic moment is not blocked along the easy axis. 
Instead, if the anisotropy energy is much greater than thermal energy, the low 
field dispersion disappears. At very low field the relaxation rate is led by a zero 
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magnetic field correlation time, which matches z, if is much lower than water 
diffusivity zv. At high magnetic fields Z1 can obtained from the maximum of a%. 
while the inflection point can be used to obtain the crystal size. The fitting to the 
Roche model of the NMRD profile thus provides an estimate of all the above 
mentioned parameters. 
 
Figure 3. 18: Longitudinal relaxivity NMRD profiles of MNP-3 (black symbols) and MNP-4 (red symbols) 
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.  
Figure 3. 19: NMRD Profile of longitudinal relaxivity for the proton water relaxation in a colloidal solution of magnetic 
nanoparticles, with the different parameters that can be derived by the fitting of the curve9. 
However, in our case neither the experimental 1H-NMRD curve of MNP-3 nor 
that of MNP-4 follow the expected trend, preventing any attempt to fit the 
experimental data. This is mostly due to the increasing values of a% at low 
frequencies, which exceed the maximum curve so that only high-frequency 
dispersion can be seen. The origin of this unexpected behaviour requires a 
much more detailed investigation which is currently in progress.  
The interpretation of the transverse relaxation profile is more complicated. 
Indeed, there are several and complex models describing the transversal 1H-
NMRD curve, whose validity is still under investigation. However, for the 
purpose of this work it is important to ascertain whether our MNPs have the 
ability to act as J$-relaxing agents, that is a sufficiently high a$ to be used, not 
only an high efficiency as therapeutic agents (Magnetic Fluid Hyperthermia, 
MFH), but also an high efficiency as diagnostic agents (Magnetic Resonance 
Imaging (MRI). To this aim we compared the a$ values of our samples with those 
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of a reference product, Endorem®, a commercial CAs based on iron-oxide 
MNPs with a diameter of 4 − 6	34 coated with dextran10. The a$ acquired at the 
characteristical frequencies used in MRI machine in hospitals are shown in 
figure 3.20, and for comparison is reported also the mean value measured for 
Endorem® at high frequency. The transversal relaxation times of both samples 
are almost 2 times faster than the commercial Endorem®. 
 
Figure 3. 20: Transverse relaxivity NMRD profiles of MNP-3 (black symbols ) and MNP-4 (red symbols) samples. The 
red dashed line represents the transverse relaxivity mean value of Endorem® at high frequency. 
The results obtained are very interesting as they show that our MNPs not only 
have the ability to increase the relaxivity of water protons, but, in terms of 
absolute magnitude, they have efficiency up to 2-3 times better than a 
commercial product such Endorem®. This result, together with the hyperthermia 
data shown above, demonstrates the possibility of using these MNPs as 
building block for the realization of theranostic nano-devices in medicine. 
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4. Assembling the MNP-HFn nano-system 
 
In the previous chapters we have presented the synthesis and characterization 
of the magnetic cores and the study of their magnetic properties for the use in 
biomedical applications. In this chapter the synthetic strategy used to 
functionalize the selected samples with ferritin protein will be described 
together with the characterization of the chemical-physical properties of the 
nano-device, MNP-HFn.  
The synthesis of the MNP-HFn system was carried out in collaboration with Dr. 
Pierpaolo Ceci and Dr. Elisabetta Falvo of IMBP-CNR of Rome, which provided 
us empty human ferritin (Fn) used for the functionalization. 
 
4.1 The Human Ferritin 
 
Figure 4. 1 Representation of the ferritin protein structure; different colours corresponds to the subunits assembled 
in spherical cage of 12 nm of external diameter and 8 nm internal diameter 
Ferritin is a highly symmetrical multimeric protein. It consists of 24 subunits that 
self-assemble into a shell-like shape, with external and internal diameters of 12 
and 8	34, respectively, which encloses a hollow cavity deputed to iron storage. 
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This protein is involved in iron homeostasis, damping the deficiency and excess 
of iron in the body by a controlled release and accumulation of Fe contained 
therein. Moreover, ferritins play an important role in the elimination of potentially 
damaging metallic ions such as: -.$L, ¥.$L, ≈3$L, ≈3$L, GX$Land o>"L 1. 
The subunits of ferritin are formed by 5 α-helices. There are two types of sub-
units with different molecular weight, called heavy (H, 21	_∆6) and light (L, 19	_∆6). The ratio between H and L is variable depending on the tissue of the 
organism considered. H subunits play a key role in detoxifying action. They are 
the only ones capable of iron oxidation from -.$L, toxic, to -."L. On the surface 
of the protein shell, at the intersection of the subunits, there are channels that 
permit iron bio-mineralization. Ferritin cavity may contain a number of atoms 
ranging from 0 (apo-ferritin) to 4500 atoms per molecule, in the form of Fe oxi-
hydroxide NPs. Depending on the tissue, ferritins have a different filling: spleen 
and liver contain on average 2000-3000 atoms of Fe, heart and brain 1000 −2000, while seldom they are totally filled. The NP of iron oxide stored inside the 
cavity has a structure that varies from monocrystalline to amorphous, and anti-
ferromagnetic properties at low temperature2. 
Recombinant ferritins made of 24 heavy chains (HFn) are endowed with 
considerable potential for the targeted delivery of drugs and diagnostic agents 
to cancer cells3–6 as they offer numerous advantageous, which include 
biosafety, water and blood solubility, amenability to multi-functionalization, and 
intrinsic ability to bind tumour cells in an effective and selective way. HFn has a 
remarkable capacity to entrap different types of molecules as CA for MRI and 
PET, organic molecules and drugs7 Importantly, HFn is one of the few 
nanoparticles that are intrinsically able to effectively and selectively bind tumour 
cells thanks to its interaction with, and internalization via transferrin receptor 1 
(TfR1)8. TfR1 is one of the most attractive cancer therapy targets, since it is up-
regulated at the surface of many types of cancers. Tumours express up to 100 
times higher levels of TfR1 than healthy cells, and actively internalize the 
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HFn:TfR1 ligand–receptor complex, to accumulate the large amounts of iron 
required for unrestrained cell growth3. This is therefore an attractive basis to 
selectively deliver HFn carrying toxic payloads to cancer lesions9. HFn has 
another notable feature: it has on the outer surface 72 lysine residues and 24 
cysteine residuals, which can be used for chemical conjugation with many 
elements as antitumor drugs, targeting agents and polyethylene glycol, PEG8.  
 
4.2 Synthesis of MNP-HFn  
The synthetic strategy followed for the MNP-HFn was based on the use of a bi-
functional polyethylene glycol (PEG) as a linker to covalently bind on one side 
the amino groups present on the surface of the MNPs coated with APPA and, 
on the other side, the –SH thiols exposed on the outer surface of the HFn. As 
mentioned in the introduction, PEG has also proven to be able to screen activity 
from the immune system, allowing increased circulation times and in vivo 
stability10. 
The covalent junction between HFn and MNPs coated with APPA, 
MNPs@APPA was obtained by using the heterobifunctional crosslinker NHS-
PEG-MAL, in which the N-hydroxysuccinimide (NHS) ester reacts specifically 
with free amino groups onto the MNPs side (Scheme 4.1a), and maleimide 
(MAL) group reacts specifically with the thiol group onto the HFn molecules 
(Scheme 4.1b). Succinimidyl-[(N-maleimidopropionamido)-dodecaethyleneglycol] 
ester, SM(PEG)12 (Thermofischer), an amine-to-sulfhydryl crosslinkers with 
soluble polyethylene glycol (PEG) spacer arms, with a 7.5	_∆6 polyethylene 
glycol (PEG) spacer was used to improve water solubility of the conjugate, and 
to minimize possible steric hindrance between MNPs@APPA and ferritin 
molecules during conjugation. 
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Scheme 4. 1: A) NHS nucleophilic substitution reaction with primary amine; B) scheme of the oxidation reaction of 
maleimide and thioether formation 
Scheme 4.2 illustrates the two-step synthesis process used: first, MNPs@APPA 
(0.1	µZ in amino groups) was reacted with 50-fold molar excess of the 
crosslinker in PBS (Phosphate Buffer Solution) suspension at pH 7.2 at room 
temperature, sonicating for 30 min. The unreacted reagent was removed by 
magnetic precipitation of the MNPs@PEG, which was washed twice with 
H2OMilliQ; Secondly, HFn was added (0.25	µZ) in PBS solution at pH 7.2, and 
sonicated for 60	4E3. at room temperature allowing the reaction with the MAL 
groups. The excess of HFn was removed by washing with PBS (10X), then 
MNP-HFn were magnetically precipitated and washed twice with H2OMilliQ. 
Figure 4.16 represents a sketch of MNP-HFn with the detail of the chemical 
bonds involved in the realization of the system. Thanks to the heat-resistance 
of ferritin, the so prepared product could be heated up to 50	°G for 30	4E3 
before being stored in the fridge at 5	°G, to ensure its sterility11. 
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Scheme 4. 2: Scheme of the two - step synthesis: (up) formation of the amide on the surface of the MNP by 
nucleophilic substitution; (bottom) Ferritin is bound by thiol nucleophilic addition on maleimide 
 
Figure 4. 2: Sketch of the MNP-HFn system and details of the linker between HFn and MNP. 
A first control of MNP-HFn formation was performed by electrophoresis on 
agarose gel. HFn and the synthesis product were run for 2 h on a 1% agarose 
gel in tris (hydroxymethyl)amminomethane hydrochloride 0.4 M under the action 
of an 80 V constant electrical field. The gel is then coloured with Kumasi blue 
to stain the protein and verify the presence of HFn onto the MNPs. Figure 4.3 
shows an image of the agarose gel. Reference HFns were free to run to the 
bottom of the gel, corresponding to the large blue spot, while the MNPs 
remained at the top of the gel. The blue colour of the MNPs spot confirm the 
presence of HFns on it, hence confirming the formation of MNP-HFn system. 
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Figure 4. 3: Image of the agarose gel after the protein staining with kumasi blue. MNP-HFn remains at the top of the 
gel while HFn run down to the bottom. 
Further demonstration of the functionalization of MNPs with HFn were given by 
CHN data (MNP-3-HFn) and ICP data (MNP-4-HFn). These data show that in 
MNP-3-HFn occurs ca. 30% of organic, while in MNP-4-HFn is ca. 40%. These 
values correspond approximately to a coverage of 4 and 6 HFn per MNP, 
respectively. 
 
4.3 Colloidal stability of MNP-FHn 
One of the crucial aspects for clinical use of MNPs is their colloidal stability in 
biological fluids and in cell culture media. Actually, to realize a stable dispersion 
of MNPs-HFn we had to found proper conditions since, although both MNP and 
MNP-HFn are perfectly stable in saline and aqueous physiological solutions, 
where they can be stored for period of time as long as 6 months, in PBS 
phosphate buffer and in culture media such as Dulbecco high modified medium 
(DMEM) both MNP and MNP-HFn lose their stability and precipitate in a few 
minutes. We initially tried to solve this problem by adding non-ionic 
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biocompatible commercial surfactants such as pluronic127 and tween20 but in 
both cases with unsatisfactory results. 
Significant improvement in the stability of the MNP-HFn system resulted from 
the use of the albumin (BSA) at 5	%	»/» solution. The addition of this protein 
allowed us to greatly improve the stability of the system, extending the stability 
from a few minutes to several hours.  
Using Dynamic Light Scattering (DLS), we estimated the hydrodynamic 
diameter of MNPs and MNP-HFn systems in water. Figure 4.4 shows the size 
distribution by volume of MNP-4 samples, while in Table 2.5 the data are 
summarized. The diameter increases from 24	34 for the MNPs to 70nm for 
MNP-HFn, while after the addition of BSA, the diameter increase up to 80nm. 
All samples are characterized by a single distribution and no aggregates were 
found. These data first of all confirm the actual junction of HFn to MNPs (the 
diameter increase is in good agreement with that expected for a MNP of 14	34 
surrounded by a HFn shell.  
 
Figure 4. 4: DLS size distribution by volume of MNP-4 (black line), MNP-4-HFn (blue line), and MNP-4-HFn with 
BSA (red line). 
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In Table 2.4 are also reported the Z-potential data. No substantial variations for 
the different samples are observed. The Z-potential of MNPs@APPA and MNP-
HFn with and without the BSA is less than −204m. 
 
Sample Sw ßS∞	 …xyz 	b¶ß@£ßß£ 24,6	34 0,274 −26,44m 
b¶ß−kÀQ 70,4	34 0,168 −21,34m 
b¶ß−kÃQ	Õ¢£	j% 80,0	34 0,186 −28,14m 
Table 4. 1: DLS data of the water suspensions, d
H
 hydrodynamic radius; PdI, polydispersivity index; Z
pot, 
Z-potential.  
We expect that BSA interact with the surface of HFn providing an enhancement 
of colloidal stability in the culture media. The increased stability can be 
explained by considering an interaction between the two proteins, BSA and 
HFn, and with the macromolecular crowding effect. Macromolecular crowding 
is an effect that occurs in macromolecule suspensions, when the concentration 
is high enough to cause significant interaction effects, such is the case of 
protein agglomeration occurring inside the cell and in physiological solutions. 
Even if counterintuitive this interaction reduces the area of surface that interacts 
with the solvent, leading to an increase in stability13,14. 
 
4.4 Atomic force microscopy characterization of MNP-HFn 
The formation of the MNP-HFn system was also investigated using atomic force 
microscopy, AFM15. AFM is a high resolution scanning probe microscopy, in 
which the imaging information is gathered by monitoring the local interaction 
between the surface of the sample and a tip mounted on deflecting cantilever: 
attractive (repulsive) interaction lead to a negative (positive) deflection that can 
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be monitored by using a laser shining the back of the cantilever. A piezoelectric 
based motor guarantees the scan of the selected area of the sample and a 
feedback loop can be used to maintain constant the interaction by changing 
the local z position of the sample (this variation directly lead to the local 
evaluation of the sample height). 
The analysis of the prepared samples was performed using the Solver P47-pro 
setup from NT-MDT, equipped with a silicon tip probe with resonance 
frequency	206,2	kHz (mod. NSG10 NT-MDT, Russia) operating in tapping 
mode16. In this mode a sinusoidal electrical potential is applied to an additional 
piezoelectric element directly mounted on the cantilever support in order to 
allow to excite the oscillation of the cantilever at a frequency corresponding to 
their resonance frequency. Initially, the tip and cantilever oscillate with a 
constant amplitude due to the free motion of this system. By approaching the 
cantilever to the sample, when the interaction between the tip and the sample 
starts to become relevant but before that the oscillation is completely stopped, 
an initial reduction in the oscillation amplitude can be detected and this 
corresponds to the tip "touching" the sample only at the minimum of its 
oscillation. Tapping mode is operated in these conditions. 
 
 
Figure 4. 5: Representation of the resonant AFM tip swing in tapping-mode. 
 
In an ideal situation, from the feedback circuit of the instrument, the height at 
which the tip is located is measured, giving a direct information on the 
morphology of the sample. Furthermore, the phase variation in the oscillating 
motion of the tip, adaptable with this set-up, offers information on the local 
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mechanical properties of the sample, which is related to differences in chemical 
composition or different stiffness of the material.  
We anticipate however that, in the following characterization the AFM system 
has been used to investigate a highly heterogeneous sample containing 
different materials with strong differences in the local stiffness and viscosity. 
These differences cannot be efficiently corrected by the feedback circuitry, thus 
leading to a complication in the origin of the contrast in the images obtained in 
both the “height” channel and in the phase contrast that we tentatively 
attributed to these local alterations. 
For the AFM characterization, a drop of an MNP-3-HFn suspension in water 
was deposited on a freshly exfoliated muscovite mica surface, then the solvent 
was evaporated under nitrogen flow and the as obtained sample was finally 
analysed with the AFM.  
  
Figure 4. 6: AFM images recorded in tapping mode: on the left, image of the height of a portion of the sample; on the 
right, image of phase contrast of the sample.  
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In Figure 4.6 are reported both the “nominal” morphology of the sample and the 
phase contrast scan. The sample appears homogeneous and includes several 
spherical objects that could be associated to the MNP-3-HFn system. We 
notice, however, that the central part of these objects presents a lower height 
that cannot be easily attributed to a real variation of the sample height. Phase 
contrast evidences a similar trend: a phase contrast inversion occurs in 
correspondence of the inner part of the detected spheres. 
In these images essentially all the observed MNP-3-HFn features a "donut" 
structure that can be better clarified by a further magnification and focusing on 
one of those structures (Figure 4.7) which confirmed that the detected features 
can be directly attributed to the core-shell structure of the MNP-HFn system. 
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Figure 4. 7: AFM images recorded in tapping mode: A) image of height; B) image of phase contrast; C) lateral profile 
of a height image; D) lateral profile of a phase contrast image. The red arrows indicate the point used to measure the 
dimension of MNP core and HFn shell. 
We notice that in the morphology (Figure 4.7a) the detected object features a 
height of 2 ± 1	34 that is lower than expected for the isolated MNP system. 
This can be attributed to the presence of an excess of surfactant in the 
deposited material. This hampers an accurate evaluation of the size of the 
particles as in an AFM analysis the z-direction is the most relevant since is less 
affected by problems due to the tip geometry. However, the longitudinal profiles 
in the morphology (Figure 4.7c) and in the phase scans (Figure 4.7d) are 
compatible with an inner MNPs of ≈ 15	34 and an HFns external shell of ≈
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17	34, in nice agreement, within the resolution limits of AFM, with the size of 
the inorganic core obtained from TEM investigations, and the value expected 
for a HFn (≈ 12	34) plus the PEG linker (≈ 4	34). 
When the phase signal (Figure 4.7b) is studied, a complex situation is confirmed 
in which the two zones with different local chemical composition can be 
distinguished, even if with a lower resolution: the inorganic nucleus, detected 
as a negative dephasing with size of ≈ 15	34 (Figure 4.7d), appears completely 
surrounded by a positive dephasing signal with size ≈ 17	34. Hence, the high 
phase contrast, > 8° between the inside and outside of the particle, and the 
donut structure highlighted in "height" gives us a confirmation on the formation 
of an outer HFn shell that covers the MNP.  
The study of the height and phase profiles of the MNP-HFn system, was 
extended to several MNP-HFns, so as to make a statistical analysis. The mean 
values obtained for MNPs, HFns and MNP-HFn are reported in table 4.2. In 
figures 4.8 and 4.9 are shown the histograms of the data collected from the 
height image profiles and the phase image profiles, respectively. The size 
distribution of the MNPs and the shell are narrow and the values fall in the 
expected range, confirming that all the MNPs analysed were uniformly covered 
with a shell of PEG-HFn.  
 
 S{y|}	b¶ß S~}ÄÄ	ß“”− kÀQ	 S&yz‘’÷− ◊ÿŸ	
Height 12,9 ± 1,6	34 18,0 ± 1,5	34 48,2 ± 2,2	34 
Phase 12,7 ± 1,9	34 17,2 ± 1,6	34 47,8 ± 2,8	34 
Table 4. 2: Diameter measured from AFM image, averaging over 220 data for Hfn, 110 for MNP and MNP-HFn. 
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Figure 4. 8: Histogram of size distribution of MNP cores and HFn shells measured from “height” images 
 
Figure 4. 9 histogram of size distribution of MNP core and HFn shell measured from “phase” images. 
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4.5 Magnetic behaviour of MNP-HFn  
 
The magnetic properties of the inorganic core were again controlled after the 
functionalization with HFn, in order to verify that no changes occurred. In figure 
4.10 are shown the hysteresis loop and a magnification of the low field region 
of MNP-3 and MNP-3-HFn samples. No significant changes were observed in 
the magnetic behaviour apart for decrease of Z1 of about 25% after the 
functionalization due to the increased amount of organic material. This value is 
in agreement with CHN data. 
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Figure 4. 10: Hysteresis loop recorded at low temperature (2,5 K): (Upper panel) Curve normalized to M
S
 of MNP-
3@APPA; (lower panel) detail at low field normalized to M
S
. MNP-3@APPA (red circles), MNP-3-HFn (purple circles). 
A similar situation was observed for MNP-4-HFn: the hysteresis loop recorded 
at low temperature does not reveal significant change in the magnetic behaviour 
after functionalization. In this case the reduction in Ms confirms the amount of 
organic shell is ca. 40% in weight.  
 
 
 91 
 
Figure 4. 11: Hysteresis loop recorded at low temperature (2,5 K), detail at low field normalized to M
S
. MNP-
4@APPA (red circles), MNP-4-HFn (purple circles). 
 
4.6 Relaxometric behaviour of MNP-HFn  
Finally, we checked the relaxation properties of MNP-3 and MNP-4 samples 
after the functionalization with HFn. In figures 4.12 and 4.13, are shown the 1H-
NMRD a% profiles recorded for the two sets of samples. 
  92
 
Figure 4. 12: : Longitudinal relaxivity, R
1
, NMRD profiles of MNP-3 (black symbols) and MNP-3-HFn (red symbols) 
 
Figure 4. 13: : Longitudinal relaxivity, R
1
, NMRD profiles of MNP-4 (black symbols) and MNP-4-HFn (red symbols) 
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Both sample display a similar behaviour. The conjugation with HFn reduces the 
longitudinal relaxivity at low frequency. In the case of MNP-3-HFn sample, the 
reduction is such that the dispersion is observed, as described in chapter 3.2.2. 
A decrease of a% values at low frequency is commonly related to a change in 
the anisotropy, but, in our case, the magnetic data do not reveal a change of 
anisotropy. Hence, the reduction of a% valuees at low frequency should be rather 
attributed to other causes, which are at present under investigation.  
In Figures 4.14 and 4.15 are shown the H-NMRD relaxation a$ profiles recorded 
for the two sets of samples and for comparison is reported also the mean value 
measured for Endorem® at high frequency. 
 
Figure 4. 14: Transverse relaxivity, R
2
, NMRD profiles of MNP-3 (black symbols ) and MNP-3-HFn (red symbols) 
samples. The red dashed line represents the transverse relaxivity mean value of Endorem® at high frequency. 
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Figure 4. 15: Transverse relaxivity, R
2
, NMRD profiles of MNP-4 (black symbols ) and MNP-4-HFn (red symbols) 
samples. The red dashed line represents the transverse relaxivity mean value of Endorem® at high frequency. 
In this case the two samples have a completely different behaviour. For MNP-
3-HFn the relaxivity remains almost unchanged, around 300	MZ%4ZZ%, while the 
MNP-4-Hfn r2 relaxivity decreases drastically from 280	MZ%4ZZ%of MNP-4 to 130	MZ%4ZZ%. To explain this different behaviour it should be emphasized that 
at high frequencies the value of a$	is strictly dependent on the minimum 
approach distance. Even if the DLS data give hydrodynamic similar radii for the 
two samples magnetic measurements, ICP and CHN revealed that MNP-3-HFn 
is coated by ca. 4 HFn while MNP-4-by approximately 6 HFn. Since MNP-4-
HFn is coated by a larger number of HFn water, on average remains at a higher 
distance from the magnetic core, producing a decrease of a$values.  
However, in terms of absolute transversal relaxivity, all samples are promising 
for biomedical application as J$ CAs. Both set of samples in fact have a a$ 
relaxivities larger than ENDOREM®, (3 times larger MNP-3-HFn and 1.5 times 
MNP-4-HFn).  
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In conclusions, the results obtained by the different techniques, gave a positive 
feedback about the realization of the desired product. The electrophoresis 
confirmed the presence of HFn linked to the MNP, DLS analysis demonstrated 
the colloidal stability of the water suspension and gave a hydrodynamic 
diameter compatible with the ones expected for the MNP-HFn system. Finally, 
by AFM analysis we obtained a topographic image of the MNP-HFn, providing 
a further proof of the success of the synthesis. We thus proceeded with the in 
vitro and in vivo test to verify the anti-tumour efficacy in MFH treatments, that 
will be described in Chapter 5. 
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5. Investigation on theranostic efficacy of MNP-HFn 
 
In the above chapters the criticalities related to the realization of a platform for 
theranostic application in the therapy of tumours based on the exploitation of 
superparamagnetic MNPs, have been discussed. Then, we have presented the 
synthesis and characterization of a hybrid system obtained through the 
functionalization of an iron oxide magnetic core with Human Ferritin. The results 
analysed so far have shown that the MNP-HFn system possesses the proper 
dimensional, chemical-physical, magnetic, hyperthermic and relaxometric 
properties, and also are stable in physiological media, which is a fundamental 
requirement for the application as heat mediator in MFH. In this chapter we 
present the results of an investigation aimed to test the antitumor efficacy of 
our product in MFH treatments, using a procedure based on the common 
specifications reported in the literature. 
Thanks to the collaboration with two different research groups we have been 
able to test the efficacy of our product both in vitro and, preliminary, in vivo for 
the treatment of tumours by MFH. In the first paragraph of this chapter we will 
discuss the results obtained from in vitro MFH treatments on three human 
cancer cell lines, performed in collaboration with Prof. Carla Ghelardini, Dr. 
Lorenzo di Cesare Mannelli and Mr.s Barbara Tenci at the laboratory of 
Pharmacology and Toxicology, Dipartimento di Neuroscienze, psicologia, area 
del farmaco e della salute del bambino (NEUROFARBA). In the following 
paragraphs the preliminary results of in vivo treatments on cavies carrying 
breast tumours, performed in collaboration with Prof. Zulmira Lacava and Mr.s 
Danyelle A. Ferreira at the laboratory of Instituto de Ciências Biológicas of the 
University of Brasilia, will be presented. 
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5.1 In vitro MFH experiment 
The experiments described in this chapter have been performed on human 
tumour cells, in particular on cell lines PC-3, prostate cancer and MDA-MB-
231, breast cancer. There are several reasons behind the choice of these cell 
lines for our experiments. First of all, the selected cell lines are extremely 
relevant since they account for 25% of all cancer cases found annually, and in 
particular the PC-3 and MDA-MB231 are the tumours with the highest incidence 
on men and women, respectively1. Second, these cell lines are the typical model 
used for the xenografted study of the corresponding tumour tissues. Most 
importantly, all these cells have the ability to internalize human ferritin via the 
transferrin receptor, Tfr1, which is over-expressed by some types of cancer 
cells, including those selected in this work. A high degree of internalization is, 
in fact, a factor considered relevant in the mechanism of induction of apoptosis 
by magnetic hyperthermia2. 
All the cancer cell lines were provided by American Type Culture Collection 
(ATCC): PC-3 was initiated from bone metastasis of a grade IV prostate 
adenocarcinoma from a 62 years old male Caucasian, while MDA-MB-231 was 
mammary gland / breast adenocarcinoma derived from metastatic site 
collected from a 51 years old female patient3. 
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5.1.1 Preliminary Analysis 
Before performing MFH experiments, it is necessary to carry out some 
preliminary tests, to verify the selected cell lines are responsive to HFn and that 
they are able to internalize both HFn and MNP-HFn. Secondly, it is necessary 
to ensure that MNP-HFns are effectively biocompatible and do not significantly 
modify cell viability. 
In Figures 5.1, and 5.2, are reported images of the two cell lines, taken at the 
fluorescence microscope, after 1h of incubation with HFn labelled with 
rhodamine (HFn-Rdh) provided by Dr. Ceci. Rhodamine is a fluorescent dye 
widely used as a tracer in biological applications since it can be easily detected 
by fluorescence microscopy (⁄;k = 550	34; ⁄;q = 580	34). The optical channel 
images were combined with the fluorescence ones, and at the fluorescence 
signal is assigned the red colour. In the images collected for MDA-MB-231 and 
for PC3, the presence into the cells of many fluorescent organelles is clearly 
observed, thus revealing that these two cell lines not only recognize HFn, but 
during the incubation they internalize large amount of apoferritins, which are 
probably confined into endosomes and lysosomes, as reported in the 
literature4. 
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Figure 5.1: Fluorescence microscope images of MDA-MB-231 cancer cells after 1h of incubation with HFn-Rhd 1	4B/4> 
 
Figure 5.2: Fluorescence microscope images of PC-3 cancer cells after 1h of incubation with HFn-Rhd 1	4B/4> 
The second preliminary characterization was to test the potential toxicity of 
MNP-HFn on the cells. To this aim the cell lines underwent the same procedure 
used for MFH in vitro experiment, which will be described in the next chapter, 
and the cell viability was investigated at two characteristic time steps: after 2h 
from the begin of the experiment, which corresponds to the time required for 
incubation plus that of exposure to AMF, and after 48	ℎ from the beginning of 
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the experiment, that is the time required to verify the thermal damages suffered 
by the cells. The viability of cells treated with MNP-HFn was compared to 
control samples using two different essays: after 2	ℎ from the beginning of the 
procedure using the Trypan blue cell count, while at the end of the experiment 
with the MTT test. Figure 5.3 (up) shows the number of vital cells, as percentage 
of the control for the two cell lines, at the concentrations of 3	4B/4? and 1	4B/4L after 2	ℎ. For both cell lines and both concentrations we did not 
observe any mortality. This result was confirmed by MTT vitality test shown in 
Figure 5.3 (bottom), which shows how after 48	ℎ from the treatment, the cells 
possess a vitality comparable to the control samples. The biocompatibility of 
the MNP-HFn system proved by this data ensures the validity of the results 
obtained in the MFH experiments that will be shown later. 
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Figure 5.3: (upper panel) Number of living cells counted at Trypan blue assay for PC-3 and MDA-MB-231 cell 
samples, after the incubation with MNP-HFn. (lower panel) MTT cellular vitality values 48h after the incubation with 
MNP-HFn. Each value is normalized to the corresponding control sample. 
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5.1.2 Analysis of the internalization of PC-3 and MDA-MB-231 cell 
lines  
 
We have proved that PC3 and MDA-MB-231 cell lines are able to internalize 
HFn and do not suffer in the presence of MNP-HFn. Now we have to verify the 
capability of the MNP-HFn system to be recognized and internalized by the 
tumour cells.  
First, exploiting the free amino groups of lysine onto the HFn surface, MNP-HFn 
were labelled with a fluorescent dye, Rhodamine. We used 5,6-
carboxymethyldamine N-hydroxysuccinimide ester (NHS-Rhodamine), 
exploiting the same reaction described in scheme 4.1A. The binding of 
rhodamine to the protein occurs by elimination of NHS by nucleophilic 
substitution of HFt free amine residues. In Figure 5.4 are reported the 
fluorimetric spectra of HFn-Rhd 5`Z (violet line), MNPs (black line) and MNP-
HFn-Rhd (red line), In the spectrum of MNP-HFn-Rhd it is clearly visible a low 
signal corresponding to rhodamine although significantly lower than that of the 
HFn-Rhd solution used as reference, whose concentration is the same as that 
expected if all the HFn reacted with Rhodamine. Such a reduction is due to a 
damping effect of the magnetite core as demonstrated in figure 5.5 where it is 
shown how the intensity of the Rhodamine signal of the solution HFn-Rhd 5	`Z, 
used as reference, is 8 fold reduced in intensity after the addition of MNPs into 
the solution (blue line). Although this damping effect of the MNPs we estimate 
the presence of ≈ 3	`Z of rhodamine in MNP-HFn-Rhd at the concentration of 14B/4? of MNPs. 
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Figure 5.4: Fluorescence emission spectra of MNPs (black line), MNP-HFn-Rhd (red line), HFn-Rhd (violet line), and 
MNPs mixed with HFn-Rhd (Blue line). 
 
Figure 5.5: Fluorescence emission spectra of MNPs (black line), MNP-HFn-Rhd (red line), and MNPs mixed with HFn-
Rhd (Blue line). 
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Thus, in order to verify the effective internalization of our product, cultures cells 
of PC3 and MDA-MB2-231were incubated for 1h with the culture medium, BSA 5%	in the presence of MNP-HFn-Rhd at two concentrations 0,1 and 0,3	4B/4? 
(4B of MNP in solution). At the end of the incubation, the samples were washed 
with culture medium and observed through laser scanning confocal microscopy 
to detect the rhodamine fluorescence. From the collected images it was 
possible to verify for both concentrations the presence of MNP-HFn within the 
cellular environment, harvested in vesicles, as previously observed for the HFn 
alone. Using the confocal microscope, it was also possible to collect images at 
different focal planes, which allows us to dissect the cell at various heights and 
to highlight the actual fluorescence inside and outside the cell. 
The sequence of images collected in Figure 5.6 shows a breast cancer cell from 
the level of the plate, towards the upper external surface of the cellular 
membrane. In all the intermediate images, it can be appreciated, the presence 
of many fluorescent vesicles scattered within the cell’s volume. Indeed, from 
these images it can be clearly distinguished the material deposited outside the 
cell, visible in the first images of the sequence (top left image in Figure 5.6), from 
the MNP-HFn that have crossed the cell’s membrane and accumulated inside.  
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Figure 5.6: Confocal microscope images of a MDA-MB-231 cell incubated for 1h with 0,1 mg/mL of MNP-HFn-Rhd. 
From top left to bottom right images are equally spaced (0,8μm) at different focus moving upwards from the plane 
of the petri to the upper surface of cell membrane. 
 
Same conclusions can be obtained by analysing the sequence of images 
reported in Figure 5.7 obtained on cancer prostate cells. Again, varying the focal 
plane, fluorescent vesicles were visible throughout the cell's internal volume, 
confirming the internalization of MNP-HFn. 
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Figure 5.7: Confocal microscope images of a PC-3 cell incubated for 1h with 0,1 mg/mL of MNP-HFn-Rhd. From 
top left to bottom right images are equally spaced (0,8μm) at different focus moving upward from the plane of the 
petri to the upper surface of cell membrane. 
We can therefore confirm that MNP-HFn is recognized by the TfR1 transferrin 
receptor and is effectively internalized within the MDA-MD-231 breast cancer 
and PC3 prostate cancer cells. 
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5.1.3 Samples preparation  
 
The procedure followed for in vitro MFH experiments here described was 
planned to simulate as close as possible the operating conditions of MFH 
treatment used in clinical trials. We worked on sterile suspension of cells, which 
where incubated with MNP-HFn and then exposed to an AMF of frequency and 
amplitude similar to those used by Prof. Andreas Jordan's team for the 
treatment of glioblastoma multiforme on human patients: 100	_\î of frequency 
and field of intensity from 4	_o4Z%up to 18_o4Z% 5–8.  
All cell lines were cultured in adhesion in the presence of the culture cell medium 
(DMEM), and then, in order to perform in vitro test, were detached from the 
surface of the cultivation flask by a treatment known as "trypsinization", where 
the cells are treated with a trypsin solution with EDTA and subsequently 
neutralized with DMEM culture medium. Trypsin is a proteolytic enzyme that 
destroys cell adhesion proteins while the function of EDTA is to prevent calcium 
and magnesium ions from sticking to the bottom of the culture vessel. 
Prolonged exposure of the cells to these substances could cause their death, 
so as soon as they are detached from the flask, it is necessary to inhibit the 
action of the proteolytic enzyme by adding a suitable volume of DMEM 
containing an inhibitor serum (α-1 antitrypsina).  
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Scheme 5.1: Sketch of the procedure used to prepare the cell samples for MFH experiment. A) 400 k cells were 
suspended in 0,5 mL of1:1 mix of DMEM a physiological solution; B) two samples were incubated with the MNP-
HFn for 1h, and D) one treated sample and one reference were exposed for 1h to the AMF while the other two were 
kept as reference. C) after incubation (step B)) 4 samples (two incubated and two control) were centrifuged and re-
suspended in 0,5mL of mix and finally D) exposed to the AMF in the same manner. 
The samples for the MFH experiments were then prepared according to the 
following steps, also resumed in scheme 5.1. A total of 400.000	7.>>M were 
suspended in 500	4? of a 1:1 mix of DMEM and physiological solution 
containing 5	%	BSA to obtain a homogeneous suspension, and incubated for 
1h in the presence of MNP-HFn at the desired concentration of magnetic 
material. A control sample was also prepared following the same procedure but 
without incubating the cells with the solution of MNP-HFn. 
In order to discriminate between the effect of extracellular global heating (i.e. 
the heating of the suspension produced by the totality of MNPs either 
internalized or not) and that of the internalized MNPs alone each sample was 
investigated both as described above and after centrifugation for 5	4E3 at 5000	aÜ4, (in the following labelled as ctrf) so as to remove all non-internalized 
MNP-HFn, and re-suspension in 500	4? of 1:1 DMEM/physiology solution mix 
at 5	%in BSA. It is known from the literature, indeed, that the local heating 
produced by internalized MNPs can trigger the apoptotic process even in the 
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absence of any sizable temperature increase2. For each sample a control was 
also prepared which was not exposed to the AMF. The samples exposed to the 
AMF, were introduced in the middle of the induction coils inside a glass 
container, thermostated at 37	°G by a flow of ethylene glycol to exclude thermal 
gradients due to coils heating and to the external environment. The field of 17	_o4Z% intensity and frequency of 183	_\î was left to operate on the system 
for 1h. At the end of the hyperthermic treatment the samples were centrifuged, 
cells were counted to the trypan blue test to check the direct effect of the 
treatment and then plated. After 48	ℎ we performed on the colony the MTT 
vitality test. This is the indicative test for effective cellular vitality as it gives a 
value that is directly proportional to cellular mitochondrial activity9. 
The adopted procedure allows a check of the effective efficacy of the 
hyperthermic treatment by comparison, for each tested concentration, of the 
control, of cells incubated with MNP-HFn, and of the action of the AMF.  
 
5.1.4 In vitro MFH treatment 
In this section, the outcomes of MFH in vitro tests will be discussed. Before the 
in vitro test on tumour cells, we measured the hyperthermic efficiency in a 
biocompatible buffer equal to that we will use in the in vitro test. Our purpose 
is to determine the concentration of the MNPs necessary to reach 42°G and 
then keep it for at least 30	4E3. We chose this threshold as temperature around ≈ 42°G were commonly reached in typical hyperthermia treatments10. In figure 
5.8 and 5.9 are shown the kinetic curves for MNP-3-HFn and MNP-4-HFn, 
respectively, suspended in saline solution containing 1X PBS and 5	%	of bovine 
serum albumin (BSA). 
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Figure 5.8: Kinetic evolution of temperature of MNP-3-HFn suspended in 0,5 mL mix 1:1of DMEM and physiological 
solution at different concentrations (1 and 3 mg/mL). The violet line indicates the 42°C threshold. 
 
Figure 5.9: : Kinetic evolution of temperature of MNP-4-HFn suspended in 0,5 mL mix 1:1 of DMEM and physiological 
solution at different concentrations (0.1 and 0.33 mg/mL). The violet line indicates the 42°C threshold. 
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The conditions that meet the above requirements were 3	4B/4? of magnetite 
for MNP-3-HFn and 14B/4? of magnetite for MNP-4-HFn. Moreover, we found 
the concentration 14B/4? and 0,3	4B/4? for MNP-3-HFn and MNP-4-HFn, 
respectively, are appropriate to investigate the MFH treatment effectiveness at 
temperature slightly below the 42°G threshold. In fact, we also want to study 
the effectiveness of the MFH treatment when the temperature reached are lower 
than that threshold and verify if there is a non-thermal antitumoural effect due 
to the MNP internalized within the cells. 
During the in vitro MFH treatment of tumour cell, it is not possible to directly 
control the T evolution, as the introduction of the temperature probe would 
cause bacterial contamination. The temperature was then measured with an 
external thermometer probe and then the real temperature was estimated 
through a calibration.  
 
5.1.4.1 MFH on PC3 
 
PC3 cell samples were treated with MNP-3-HFn (1	h) at the two concentrations 
identified in the experiments previously described, i.e. 1 and 3	mg/mL. For each 
concentration, two samples were investigated, one centrifuged before being 
exposed to AMF and one not centrifuged. At the end of the application of the 
AMF (1	h), living cells were counted at the optical microscope after the stain 
with trypan blue. 
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Figure 5.10: Number of PC3 living cells counted at Trypan blue assay. Each value is normalized to the 
corresponding control sample. 
Figure 5.10 shows histograms of the percentage of living cells counted in the 
samples referred to the controls, taken as 100	%. The data show an unusual 
behaviour: samples treated with MNP-HFn and exposed to AMF generally 
suffer a 20%	reduction only, with the exception of the non-centrifuged sample 
at 3	4B/4? of MNP-HFn which shows a significant reduction of 70	% of the 
number living cells. Samples incubated at 3	4B/4?but not exposed to the AMF 
did not suffer any change in cell viability. These results suggest that the 
significant reduction of living cells in the sample exposed to the AMF has been 
induced by a direct thermal damage due to a global temperature increase 
during the treatment. MTT data, obtained at 48	ℎ from AMF treatment, 
confirmed this result. 
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Figure 5.11: MTT cellular vitality assay on PC3 cell at 48h from the hyperthermic treatment. Each values are 
normalized to the corresponding control sample. 
In the MTT vitality histogram, shown in Figure 5.11, a large reduction of the 
vitality of cells is observed for the 3	4B/4? samples, equal to 50	% and 90	% 
for centrifuged and non-centrifuged one, respectively. The other samples show 
only slight variations in vitality, which are not adequate for an efficient 
anticancer treatment. 
The kinetic evolution of external temperature recorded during the MFH 
treatment, are shown in figure 5.12. These curves reveal that, as expected, non-
centrifuged samples reach an internal estimated temperature higher (≈ 43	°G 
for 3	qÅq+) and lower (≈ 40	°G for 1	4B/4?) than the 42	°G threshold. Conversely, 
the estimated internal T of centrifuged 1	4B/4? sample increases only up to ≈39°G; while the centrifuged 3	4B/4? sample reaches a greater temperature, 
slightly below 42°G. The samples heated up to J < 40	°G, were not affected by 
any thermal damages. Therefore, complete cell death was obtained only in the 
sample with the highest rise in temperature, corroborating the hypothesis that 
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MFH therapy is effective for those samples that reached or exceeded 42	°G 
during the treatment thanks to the heating of the environment. No effects arising 
from local intracellular heating seems to be effective on our samples.  
 
 
Figure 5.12: Temperature evolution during the MFH treatment, on PC3 cells incubated with MNP-3-HFn.  
 
5.1.4.2 MFH on MDA-MD-231 
MDA-MD-231 cell samples were treated with MNP-3-HFn and with MNP-4-
HFn, respectively, using the concentrations identified as the best ones in the 
experiments described in section 3.1.3.4, i.e. 1 − 3	mg/mL for MNP-3-HFn, and 0,3 − 1	mg/mL for MNP-4-HFn. Also in this case the cell suspensions were 
exposed to the AMF both before and after centrifugation. In figure 5.13 are 
shown the histograms of the living cells counted with the trypan blue assay at 
the optical microscope after the treatment with AMF. 
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Figure 5.13: Number of living MDA-MB-231 cells counted at Trypan blue assay after the hyperthermic treatment. 
Each value is normalized to the corresponding control sample. MNP-3-HFn in the upper panel; MNP-4-HFn in the 
lower panel. 
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Unlike PC3, after the MFH treatment the number of living MDA-MB-231 cells 
for the non centrifuged samples ishigher, being 66	%	and 68	% for MNP-3HFn 
at	1	4B/4? and at 3	4B/4?, respectively, and 72	% and 52	% for MNP3-HFn 
at	0,3	4B/4?and 1	4B/4?, respectively. Similarly, also for the centrifuged 
samples the number of living cells is much larger than in the PC3 case, the 
effect of the AMF on the cell viability being almost negligible. Indeed, after the 
MFH treatment the cell viability was for MNP-3-HFn 88	% at 1	4B/4? and 81	% 
at 3	4B/4?; and for MNP-4-HFn 95	% at	0,3	4B/4? and 108	% at 1	4B/4?. 
This result suggests that all the non-centrifuged samples, have suffered direct 
thermal damage during the treatment, even if to a lower extent with respect to 
the previous experiment. No significant change in the number of living cells 
were seen for the treated cells not exposed to the AMF, as previously seenfor 
the PC3 samples. 
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Figure 5.14: MTT cellular vitality of MDA-MB-231 cells at 48h from the hyperthermic treatment. Each value is 
normalized to the corresponding control sample. MNP-3-HFn is reported in the upper panel, MNP-4-HFn in the lower 
panel. 
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The MTT vitality histogram, shown in Figure 5.14, confirms the previous data. 
Indeed, the only significant variations in cell vitality are observed for the samples 
treated at the highest concentration of 3 mg / mL for MNP-3-HFn and 1mg/mL 
for MNP-4-HFn: all cells of these samples, indeed, seem to have been damaged 
by the external temperature which dramatically compromised their vital 
functions, rather than by an intracellular heating mechanism. All other samples 
did not show any significative decrease of cell vitality. 
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Figure 5.15: Temperature evolution during the MFH treatment on MDA-MB-231 cells incubated with MNP-3-HFn 
(upper panel) and MNP-4-HFn (lower panel). 
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As expected the evolution of temperature recorded during the MFH treatment, 
reported in figure 5.15, reveals that only samples at the higher concentration 
reaches J ≈ 43,3	°G, while all the others reach a temperature lower than 42	°G	during the treatment. The samples that do not overcome 42	°G do not 
show any reduction in cell viability. Indeed, only samples that overcome 42	°G 
show a total reduction of cell viability, as if the mechanism responsible of the 
cell death were only the thermal damages due to the temperature reached. 
To verify these results we tested the effect of standard heating on cells, that is, 
some PC3 cells were prepared according to the same procedure used for the 
MFH in vitro test and immersed in a thermal bath for growing times at 44	°G and 48	°G. Figure 5.16 shows the results of the trypan blue cell count after the 
thermal treatment. For both temperatures, a dose-dependent effect is visible: 
the samples heated at 44°C show a progressive reduction in the number of 
living cells of 15	% for C = 10	4E3, 25	% for C = 20	4E3, up to 50	% for C =30	4E3. The samples heated at 48	°G, instead display a reduction in viability of 50	% for C = 10	4E3, 70	% for C = 20	4E3, and 80	% for C = 30	4E3. 
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Figure 5.16: Number of PC3 living cells counted at Trypan blue assay after the thermal treatment. Each value is 
normalized to the corresponding control sample. 
After 48	h (MTT analysis, figure 5.17) a more dramatic dependence on the time 
of immersion in the thermal bath is observed at 48	°G, since all the samples 
have suffered thermal damages. Conversely, for the samples heated at 44	°G a 
gradual reduction in vitality is observed. We can thus conclude that heating for 30	4E3 at 44	°G is not a thermal dose large enough to lead all cells to death. 
These data are in contradiction with our experimental results, as the 
hyperthermic treatment seems to induce critical damages for lower maximal 
temperature and time intervals.  
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Figure 5.17: MTT vitality essay on PC-3 cells, at 48 h from the thermal treatment. Each value is normalized to the 
corresponding control sample. 
In order to rationalize this result it can be helpful a comparison with literature 
data on resistance to hyperthermic treatments of in vitro cellular samples. 
Human cells generally have higher resistance to thermal treatments than other 
animal cells and therefore need higher thermal doses (TD), commonly defined 
as equivalent cumulative minutes of treatment at 43	°G10. However, the duration 
and temperature required to realize an efficient hyperthermic treatment are still 
under debate11. In general, a "breakpoint" at 43	°G is observed in in vitro human 
cells12. Indeed, to obtain the same therapeutic effect of a hyperthermic 
treatment at J = 43	°G and time C = 	 C#" for a higher temperature, J = 43 + 3 it 
is required C = C#" 23v ; conversely, for lower temperature, J = 43 −4 it is 
needed C = C#" × 4411. Then, we can introduce the thermal isoeffective dose 
(TID) as the time in minutes at 43	°G (EM43) which corresponds to the thermal 
dose administrated keeping a system at Jr for the time Cr. TID can be evaluated 
with the formula: 
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JÆ∆ = fiZ43	 = 	 Cr ∙ p(#"Z-Q) 
where p is a conversion factor to compensate 1°G temperature change above 
or below the breakpoint. Human cells usually have p ≈ 0,25 below the 
breakpoint and p ≈ 0,5 over the breakpoint11. The dependence of the thermal 
dose on temperature and time of application of the AMF for the desired 
therapeutic effect is shown in Figure 5.1812. 
Our results are consistent with this model. However, if on the one hand the 
ineffectiveness of treatments that did not reach 43	°G it is not unexpected, on 
the other the large mortality observed in MFH treatments performed at 43	°G 
suggests  
 
Figure 5.18: Isoeffect curve of the treatment time vs. treatment temperature for hyperthermia( taken from Dutz et 
Hergt12). 
that internalized MNPs can provide an additional contribution which enhances 
the efficacy of the treatment.  
The MNP-HFn internalized into the cells may indeed play an adjuvant role 
providing a direct inner damage which, combined with the external increment 
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of temperature, can lead to a stronger efficacy of the MFH treatment. This is an 
important indication that deserves further in-depth study in the next future. The 
knowledge of the mechanism of heating is in fact crucial also to establish the 
best way to deliver the magnetic material between active targeting, that permits 
to cross the cell membrane, or accumulation of MNPs in the extracellular matrix 
by the EPR effect only.  
 
5.2 In vivo test of MNP-HFn  
All the results obtained so far have shown the system MNP-HFn is a promising 
candidate to be used as theranostic agent in the therapy of tumours. Therefore, 
we decided to deepen the characterization of our nano-system by investigating 
the in vivo biodistribution, the toxicity and genotoxicity and the antitumor 
efficacy of MFH treatment with MNP-HFn. Most of these experiments are still 
in progress. Here, however, the preliminary results obtained by experiments 
carried out on female Swiss albino mice, bearing Ehrlich ascitic breast tumour, 
are described. These experiments were performed by Prof. Zulmira Lacava and 
Mr.s Danyelle A. Ferreira at the laboratory of Instituto de Ciências Biológicas of 
the University of Brasilia (Brazil). 
 
5.2.1 Toxicity evaluation 
Initially, the female Swiss albino mice were randomly distributed in treatment 
and control groups (5 groups; 6 mice/group), following the guidelines for the 
design and statistical analysis of experiments using laboratory animals for a 
pilot study14. Mice groups were intraperitoneal injected, with dose tuned 
according to their weight, during 8 consecutive days with three different 
concentrations of MNP-HFn suspensions, and compared to negative control 
(injected with PBS) and to a positive control which was injected with 
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MethylMethaneSulfonate (MMS). MMS is a mutagenic substance commonly 
used as positive control as described in the Organisation for Economic Co-
operation and Development (OECD) guideline15. In scheme 5.2 are summarized 
the different treatments for the various groups selected. 
 
Scheme 5.2: Diagram of the treatment received by each group of mice. 
 
5.2.2 In vivo investigation of the potential toxicity of MNP-HFn 
 CN CP C1 C2 C3 
WBC 103/uL 3,1 ± 0,4 2,65 ± 1,0 4,86 ± 0,7 5,0 ± 0,6 3,8 ± 0,2 
RBC 106/uL 8,3 ± 0,3 8,5 ± 0,2 7,98 ± 0,3 8,5 ± 0,4 8,2 ± 0,3 
HGB g/dL 12,3 ± 0,3 12,1±0,4 11,65 ± 0,6 11,6 ± 0,6 11,6 ± 0,5 
HCT % 31,2 ± 1,0 31,85 ± 0,9 30,2 ± 1,2 31,1 ± 1,8 30,5 ± 1,3 
MCV fL 37,5 ± 0,5 37,6 ± 0,7 37,8 ± 0,3 36,6 ± 0,5 37,2 ± 0,4 
MCH pg 14,8 ± 0,3* 14,3 ± 0,3 14,6 ± 0,2 13,7 ± 0,2* 14,1 ± 0,2 
MCHC g/dL 39,6 ± 0,6* 38,0 ± 0,1 38,5 ± 0,5 37,3 ± 0,3* 37,9 ± 0,2 
PLT 103/uL 1013,2 ± 145,5 
893,33 ± 
81,3 
990,7 ± 
140,3 
1326,2 ± 
175,0 
1048,5 ± 
63,9 
Table 5.3:Haematological analysis performed 24h after the last treatment: WBC, white blood cells; RBC, red blood 
cells; HGB, haemoglobin; HCT, haematocrit; MCV, mean cell volume; MCH, mean cell haemoglobin; MCHC, mean 
cell haemoglobin concentration; PLT, platelet. 
Negative Control 
(CN)
•6 animals
•PBS intraperitoneal
Positive Control (CP)
•6 animals
•MMS/50mg/Kg/die 
intraperitoneal
Concentration 1 (C1)
•6 animals
•6,25 mg/Kg/die 
intraperitoneal
Concentration 2 (C2)
•6 animals
•12,5 mg/kg/die 
intraperitoneal
Concentration 3 (C3)
•6 animals
•25 mg/kg/die 
intraperitoneal
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In vitro tests suggested that MNP-HFn is non-toxic. In order to confirm this 
result in vivo, the groups of animals underwent to different tests: haematological 
and biochemistry analysis, feed intake and weight of organs. Organs and blood 
for these exams were collected 24h after the last treatment. At first we 
performed the haematological analysis. The haemograms, reported in table 5.1 
revealed no significant changes in the main haematological parameters of all 
the investigated animals. The biochemistry analysis, reported in table 5.2, also 
provided precious information on MNP-HFn biocompatibility. In fact, an 
increase in the value of glutamate-pyruvate transaminase (GPT), glutamate-
oxalacetate transaminase (GOT) and alkaline phosphatise are indicative of liver 
damages, creatine a urea of kidney damages, while lactate dehydrogenase 
(LDH) is a signal of general tissue damages. In general all the parameters of the 
animals treated with MNP-HFn did not show any significant deviation. Indeed, 
only for the positive control a high value in glutamate-oxalacetate transaminase 
(GOT) was observed, indicating liver damages. This result is not surprising since 
liver is one of the target tissues of MMS (proof of these damages will be however 
obtained by histological analyses, under way). The absence of any statistical 
difference in all the other values have to be combined with the histological 
analysis, currently in progress, to assure that the MNP-HFn did not cause any 
damage to any organs.  
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 CN CP C1 C2 C3 
GPT (ALT) -U/L 17±3,8 32,2±4,9 30,2±3,4 21,67±3,116 27,83±1,014 
GOT (AST) -U/L 57±6,* 114,7±7,8* 94,3±14,9 70,83±9,6 105,3±22,65 
CREATININE 
(mg/dL) 0,32±0,02 0,31±0,01 0,36±0,03 0,27±0,02 0,30±0,01 
ALKALINE 
PHOSPHATASE 
(U/L) 
11,33±1,89 9,16±0,91 9,00±0,81 10,67±1,60 5,83±2,18 
IRON (µg/dL) 166,8±16,8 171,2±37,2 138,2±37,2 188,0±44,3 275,8±21,5 
LDH mg/dL 703±242,1 1031±178,3 678,5±101,5 778,0±99,78 558,5±30,05 
UREA 
(mg/dL)22 49,5±3,4* 50,7±6,6 45,3±4,08 34,0±1,1* 37,0±2,2 
Table 5.4 Biochemical analysis 24 h after the last treatment: glutamate-pyruvate transaminase GPT(ALT); glutamate-
oxalacetate transaminase GOT(AST); Creatinine; Alkaline phosphatase; Iron; Lactate dehydrogenase, LDH; Urea. 
The body weight and feed intake of the 5 groups of mice were monitored 
during the experiment, and the results are shown in Figure 5.14. No statistical 
differences were found neither in the weight nor in the feed intake among the 
groups during the 9 days of treatment with the only exception of the positive 
control group, which exhibits higher values of feed intake. This result, 
therefore supports once more the biocompatibility of our sample. 
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Figure 5.19: (upper panel) Mean weight chart of the mice groups during the experiment. (lower panel) Feed intake 
chart of the mice groups on day 3-5-6-9 of the experiment. 
The weight of the liver and spleen after explanation at the end of the treatment 
was also determined and the obtained data are shown in Figure 5.15. In the 
groups treated with MNP-HFn a clear trend of the weight of the organs with the 
administered iron oxide dose per kg is observed. This behaviour is coherent 
with the progressive increase of iron administrated and fully consistent with 
literature data16, thus confirming that no anomalies occurred when MNP-HFn 
was injected in mice. 
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Figure 5.20: Mean weight of the mice group liver (upper panel) and spleen (lower panel) after the biocompatibility 
test. 
In conclusion, all the analyses performed until now show no change in the vital 
parameter of the mice indicating that the non-toxicity of MNP-HFn is preserved 
in vivo. The results of histopathology and genotoxicity tests (comet assay, 
micronucleus, and DNA fragmentation) are currently under way, but data are 
not available yet.  
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5.2.3 In vivo validation of the MFH efficacy 
After validation of the biocompatibility of our product we proceeded with the 
evaluation of its efficacy in in vivo treatment of tumour by MFH on mice. To this 
aim the female Swiss albino mice initially were randomly distributed among the 
treatment and control groups (7 groups; 6 mice/group), following the guidelines 
for the design and statistical analysis of experiments using laboratory animals 
for a pilot study14. 
The seven Swiss albino mice groups received the following treatment: 
• M-Ctr, control group; no treatment; 
• M-NP(EV), control group; mice injected intravenously with MNP-HFn, 
• M-T-Ctr, control group; tumour bearing mice, no treatment; 
• M-T-NP(IT), control group; tumour bearing mice, injected intratumour 
with MNP-HFn; 
• M-T-AFM, tumour bearing mice exposed to AMF; 
• M-T-NP(IT)-AFM, tumour bearing mice, injected intratumour with MNP-
HFn and exposed to AMF; 
• M-T-NP(EV)-AFM, tumour bearing mice, injected intravenously with 
MNP-HFn and exposed to AMF. 
In Figure 5.14 the different treatment received by each group are schematically 
resumed: 
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Figure 5.21: Schematic representation of the different treatments applied on seven groups of Swiss albino mice. On 
the top right side is the legend of the symbols used to differentiate among the various groups. MNP-HFn was injected 
either intravenously (EV) or directly in the tumour (IT). : 
 
The mice groups received a 10 days treatment during which they were injected 
and/or exposed to the AMF. The protocol of the treatment for each group and 
the administered dose as reported in table 5.3. 
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Group Day 1 Day 3 Day 5 Day 7 Day9 
M-Ctr Placebo	 Placebo Placebo Placebo Placebo 
M-NP(EV) 80µ>	 80µ> 80µ> 80µ> 80µ> 
M-T-Ctr Placebo	 Placebo Placebo Placebo Placebo 
M-T-NP(IT) 100µ>	 80µ> 60µ> 80µ> 60µ> 
M-T-AFM Placebo AFM	 Placebo AFM Placebo AFM Placebo AFM Placebo AFM 
M-T-NP(IT)-AFM 100µ> AFM 80µ> AFM 60µ> AFM 80µ> AFM 60µ> AFM 
M-T-NP(EV)-AFM 80µ> AFM 80µ> AFM 80µ> AFM 80µ> AFM 80µ> AFM 
Table 5.5: Scheme of the MFH experiment; details of the injection and AMF treatment received. 
Mice were injected with physiologic solution as placebo while the treated mice 
received the MNP-HFn with injection of 100 − 80 − 60	µ> at 10	4B/4?; mice 
injected intratumourly received different injection following a procedure 
identified by Lacava’s group, while the mice injected intravenously received 
always the same amount due to difficulties found in administering larger dose 
intravenously.  
The AMF equipment used for the experiments is shown in Figure 5.17 A and B. 
It is a in-house built radio frequency hyperthermia (RF-HT) portable apparatus 
developed by Lacava’s research group, CMagMHG17,18, The set-up is 
constituted by one cylindrical metallic rod of 10.7 mm diameter, closely wound 
by a coil of wire concentrating the alternating magnetic flux. The solenoid core 
is linked to a moveable support to apply the magnetic field in the targeted 
region19. 
  136
Mice were exposed for 30 min to an AMF of 3,18	_o4Z% field amplitude and 1	Z\î frequency. 
 
Figure 5.22:Images of the equipment employed to evaluate in vivo the efficiency of MNP-HF to reduce tumour growth 
by MFH (A) portable apparatus developed by Lacava’s research group (CMagMHG); (B) Application of the AMF on 
the animal. 
In order to evaluate separately the short-term and long term efficacy of the 
therapy, after the last treatment each group was separated in 2 subgroups (3 
animal/group), and analysed after 2	and 10	X6∂M respectively. Each subgroup 
is identified by the suffix -2 and -28, to identify the number of days spent before 
the analysis.  
During all the experiment mice were weighted to check their health. Although 
the complete analysis is still in progress, here we briefly present the preliminary 
results obtained from comportamental behaviour, mice weight, tumour volume, 
spleen and liver weight and haematological and biochemistry analysis.  
Figure 5.18 presents the animal weight evolution since the day of the beginning 
of treatments in tumour bearing animals until 2	X6∂M after the end of the 
experiments, at day 12. Animals in fact received the NP-HFn injection on day 2, 4, 6, 8, and	10. 
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Figure 5.16: Mean weight chart of the mice groups from the beginning to 2 days after the end of the hyperthermia 
treatment. 
Comparing control mice in group M-Ctrl and M-NP(EV), the injection of MNP-
HFn had no significant effect on health animal weight. Conversely, tumour 
bearing mice display loss of weight during the investigate time range. This 
behaviour is indeed expected as the tumour itself causes severe alterations, 
which however appear to be partially relieved by the MFH treatment. 
Figure 5.19 shows the animal weight evolution for 28	X6∂M starting from the end 
of the treatment (X6∂	10 of figure 5.18) in tumour bearing animals. 
 
 
Figure 5.17: Mean weight chart of the mice groups during the 28 days after the end of the hyperthermia treatment. 
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These data confirm the result observed previously, that the intravenously 
injection of MNP-HFn did not cause alteration in the weight of healthy animals, 
and thus that MNP-HFn is non-toxic. If this would not be the case, indeed, we 
would expect some comportamental alterations which would result in a loss of 
weight. The uphill trend at the end of the graphics were due to the natural weight 
gain in the last three weeks. 
The volume of tumours implanted in the mice was also monitored during the 
experiment. The upper panel of figure 5.20 shows the evolution of the tumour 
volume in the mice sacrificed two days after the last treatment and, lower panel, 
in mice sacrificied 28	X6∂M after the ends of the treatment.  
 
 
 
Figure 5.18: (Upper Panel) Charts of the tumour growth in mice groups from the beginning to 2 days after the end of 
the hyperthermia treatment. (Lower Panel) Chart of the tumour growth in mice groups 28 days after the end of the 
treatment. 
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The tumour volume steadily increases during the first part of the experiment 
(X6∂M	1 − 8) for all the groups, but in the last days of the experiment mice 
treated with MFH show a significant decrease in tumour size compared to the 
control group, the most relevant result being observed for the group treated 
with MFH after intravenous injection of MNP-HFn. Albeit lower, a decrease of 
the tumour size is also visible for M-T-NP(IT)-AFM and M-T-NP(IT). However, 
for longer time, after the end of the treatment, all the groups presented an 
increase of tumour volume. Even if the statistical set of these preliminary data 
is still small and there are same anomalies a clear trend emerges: treated mice 
present a decrease in tumour volume during the treatment and a lower increase 
in the regrowth after the end of the treatment. Furthermore, intravenous 
treatment shows a better efficacy compared to the intratumour one.  
These very promising results need to be confirmed by other analyses currently 
in progress. Indeed, after being sacrificed the spleen, liver, brain, lung, kidney, 
lymph nodes, health breast and bone marrow cells and tumours were collected, 
for the following analysis: 
• histological analysis coupled to ICP analysis, to search for possible 
metastasis, histological abnormalities and to reveal the biodistribution 
of nanoparticles; 
• biochemistry and haematological blood analysis: to observe toxicity 
effects, such as liver, kidney and other tissue damages; 
• genotoxicity and cytotoxicity analysis: to evaluate the DNA and cell 
damages; 
• microtomography analysis to follow tumour growth evolution. 
In conclusion, although preliminary, in vivo investigation has clearly shown that 
the administration of MNP-HFn, even when systemic (EV application) did not 
cause any adverse effect on mice in terms of biochemistry and haematological 
alteration. Most importantly, the application of an AMF even of very low 
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amplitude, induced a partial tumour regression. These results made the nano-
system synthesized in this work an extremely appealing platform for the therapy 
of selected tumours such as breast cancer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 141 
1. Fitzmaurice, C. et al. Global, Regional, and National Cancer Incidence, 
Mortality, Years of Life Lost, Years Lived With Disability, and Disability-
Adjusted Life-years for 32 Cancer Groups, 1990 to 2015. JAMA Oncol. 
3, 524 (2017). 
2. Fantechi, E. et al. A Smart Platform for Hyperthermia Application in 
Cancer Treatment : Cobalt-Doped Ferrite Nanoparticles Mineralized in 
Human Ferritin Cages. 4705–4719 (2014). 
3. American Type Culture Collection. Available at: 
https://www.lgcstandards-atcc.org/.  
4. Li, L. et al. Binding and uptake of H-ferritin are mediated by human 
transferrin receptor-1. Proc. Natl. Acad. Sci. 107, 3505–3510 (2010). 
5. Maier-Hauff, K. et al. Efficacy and safety of intratumoral thermotherapy 
using magnetic iron-oxide nanoparticles combined with external beam 
radiotherapy on patients with recurrent glioblastoma multiforme. J. 
Neurooncol. 103, 317–324 (2010). 
6. Thiesen, B. & Jordan, A. Clinical applications of magnetic nanoparticles 
for hyperthermia. Int. J. Hyperth. 24, 467–474 (2008). 
7. Johannsen, M. et al. Thermotherapy of Prostate Cancer Using Magnetic 
Nanoparticles: Feasibility, Imaging, and Three-Dimensional 
Temperature Distribution. Eur. Urol. 52, 1653–1662 (2007). 
8. Reilly, P. J. Applied Bioelectricity From Electrical Stimulation to 
Electropathology. 28, (1998). 
9. Abel, S. D. A. & Baird, S. K. Honey is cytotoxic towards prostate cancer 
cells but interacts with the MTT reagent: Considerations for the choice 
of cell viability assay. Food Chem. 241, 70–78 (2017). 
10. Behrouzkia, Z., Joveini, Z., Keshavarzi, B., Eyvazzadeh, N. & Aghdam, 
R. Z. Hyperthermia: How can it be used? Oman Med. J. 31, 89–97 
(2016). 
11. Dewhirst, M. W., Viglianti, B. L., Lora-Michiels, M., Hanson, M. & 
Hoopes, P. J. Basic principles of thermal dosimetry and thermal 
thresholds for tissue damage from hyperthermia. Int. J. Hyperth. 19, 
267–294 (2003). 
12. Dutz, S. & Hergt, R. Magnetic particle hyperthermia—a promising 
tumour therapy? Nanotechnology 25, 452001 (2014). 
13. Dewey, W. C. Arrhenius relationships from the molecule and cell to the 
clinic. Int. J. Hyperth. 25, 3–20 (2009). 
14. Festing MF, A. D. Guidelines for the design and statistical analysis of 
experiments using laboratory animals. ILAR J 244–258 (2002). 
  142
15. (OECD) guideline 474. Available at: 
http://www.oecd.org/daf/inv/mne/48004323.pdf.  
16. Lacava, L. et al. Long-term retention of dextran-coated magnetite 
nanoparticles in the liver and spleen. J. Magn. Magn. Mater. 272, 2434–
2435 (2004). 
17. MHA, G. et al. Proposal of amagnetohyperthermia system: preliminary 
biological tests. J. Magn. Magn. Mater. 2406–7 (2004). 
18. Guedes MHA, Lacava ZGM, Guedes MEA, da Silva MF, M. P. Portable 
radio-frequency electromagnetic field generator. PI0204433-1 (2002). 
19. KP, T. et al. Radio frequency radiation-induced hyperthermia using Si 
nanoparticle- based sensitizers for mild cancer therapy. Sci. Rep. 7034 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 143 
6. The MNP-HFn as Drug Delivery system 
 
We have demonstrated that the MNP-HFn system has a good antitumoural 
activity both in vitro and in vivo, when used as heat mediator in the MFH 
treatment. On the basis of these promising results, we attempted to imprve the 
cytotoxic efficiency of this platform by adding a further functionality. In 
particular, we exploited the capability of the internal cavity of HFn to host 
moderately hydro-soluble molecules, to load MNP-HFn with a chemotherapic 
drug, doxorubicin (DOXO), and to use it as a carrier for in situ delivery.  
 
In this chapter we will describe the synthesis and characterization of this novel 
hybrid nano-device, MNP-HFn(DOXO) with multifold functionalities for 
antitumoral treatment. This system exploits on one hand the proteic component 
HFn(DOXO) to target cancer cells and to carry DOXO directly at the tumour site, 
and on the other the capability of the inorganic core to release heat upon 
application of an AMF and act as CA for MRI. Such a platform combines in a 
single system three main functionalities for the enhanced treatment of tumours, 
early diagnosis, drug delivery and hyperthermia therapy, constituting an ideal 
and powerful candidate for the theranostic approach in the tumour treatment.  
 
6.1 Doxorubicin and Ferritin 
 
The anthracycline antibiotic doxorubicin (Adriamycin), whose formula is 
sketched in Figure 6.1, was originally isolated from the fungus Streptomyces 
peucetius1. It is a chemotherapeutic drug acting as intercalating agent by 
inhibiting duplication of DNA and mitotic cell. DOXO has a strong activity 
against a wide range of human malignant neoplasms, including acute 
leukaemia, non-Hodgkin lymphomas, breast cancer, Hodgkin's disease and 
sarcomas2. Apart from side-effects that are common to many cancer 
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chemotherapeutics, i.e. hematopoietic suppression, nausea and vomiting, and 
alopecia, the clinical usefulness of doxorubicin is largely limited by a cumulative 
dose-related cardiomyopathy that manifests itself as congestive heart failure3. 
 
Figure 6. 1: Doxorubicin structure. 
 
The implementation of a drug delivery system capable of an effective in situ 
release of DOXO by reducing side effects is widely discussed in the literature4–
6. An interesting result in this sense has been recently proposed by P. Ceci et 
al. who patented an innovative encapsulation system for doxorubicin using a 
genetically modified HFn7. The HFn was genetically modified by enriching each 
subunit with a proline/alanine/serine (PAS) polypeptide, resulting in an 
enhanced capability to encapsulate DOXO with respect to wild ferritin and 
offering the additional benefits of higher half-life in plasma and stability8. 
 
 
Figure 6. 2 Schematic representation of the DOXO encapsulation process. Protein in its native folding was 
denaturated at low pH in the presence of DOXO, then at neutral pH it recovers its folding with the cavity filled of 
DOXO. 
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DOXO was encapsulated within the protein cavity of the HFns by exploiting the 
protein deassembling-assembling process as a function of the pH, schematized 
in Figure 6.2. In physiological conditions, HFn is assembled in 24 subunits, but 
when the pH decreases to less than 2, the protein unfolds. If the pH is increased 
again up to neutrality, the protein folds back and the DOXO in the environment 
remains trapped within the macromolecule9–12. The inner surface of ferritin is 
charged negatively while the DOXO molecules are protonated at physiological 
pH, the electrostatic interaction thus favors the adsorption of the drug. Usually 
wild HFn can store ≈ 	30 DOXO per molecules, however, when modified with 
PAS polypeptide, the number can increase up to 60 – 9010. Indeed, these 
disordered peptides are known to increase the stability of a number of 
biopharmaceutical10. 
The DOXO filled, genetically modified HFns were prepared by Dr. Pierpaolo Ceci 
and Dr. Elisabetta Falvo following the procedure reported in their patent7. The 
DOXO encapsulation in HFn cavity was also confirmed by the change of colour 
of the suspension (Figure 6.3). 
 
 
Figure 6. 3: Solutions of HFn (a) and DOXO(b) and HFn(DOXO) (c) are differently coloured (colourless, magenta and 
amarant respectively. 
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An evaluation of the amount of DOXO loaded on the HFn was obtained 
exploiting the optical properties of the drug. DOXO, indeed, has an absorption 
peak at 500	34, as shown in Figure 6.4, where the UV-Vis spectrum of 
HFn(DOXO)disrupted in (HCl1	Z):(isopropyl alcool) 1:1, is reported. The amount 
of DOXO was then determined measuring the absorption at 485	34 using a 
calibration curve obtained with DOXO standard solutions. We found a DOXO 
concentration of 2	4Z corresponding to 60 DOXO in each HFn, as expected.  
 
 
Figure 6. 4: Absorption spectrum of HFn(DOXO) solution after the denaturation. 
 
6.2 Synthesis of MNP-HFn(DOXO) 
The synthesis of MNP-HFn(DOXO) was performed following the same steps 
used for MNP-HFn and described in chapter2.1. In the next paragraphs are 
briefly described the characterization of the MNPs, the synthesis and 
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characterization of MNP-HFn(DOXO) and the preliminary in vitro analysis of its 
antitumoral activity. 
 
6.2.1 Synthesis and characterization of MNP-HFn(DOXO) 
The MNPs were synthesized by thermal decomposition of -.(6767)"using the 
same conditions described in Chapter 2.1. In a 3 neck flask 8	44=> of -.(6767)", 8	44=> of oleic acid (OA) and 8	44=> of oleylamine (OAm), were 
dissolved in	110	4? of benzylether and the reaction mix was heated under a 
flux of nitrogen up to 200	°G in 15	4E3, kept at this temperature for30	4E3, and 
finally heated to reflux and kept there for 1	ℎ. The MNPs powder, named in the 
following MNP-6, was washed 3 times with isopropyl alcohol, dried and 
analysed by XRD. The XRD diffraction pattern of MNP-6, shown in figure 6.5, 
matches that of bulk magnetite. The Pawley analysis of the pattern gives a 
lattice parameter 6 = 8,403	Å	and crystal size X = 15,6	34. 
 
Figure 6. 5: XRD Patterns of samples MNP-6. The red bars correspond to the reference pattern of magnetite (PDF 
65-3107) 
The statistical analysis of diameter performed on TEM micrographs, gave the 
size distribution shown in figure 6.6. MNP-6 has a broad distribution centred at X-./ = 13,8 ± 2,1	34 and the MNP shape is faceted. The fitting of the 
distribution with a Log Normal function gave a mean size X+, = 13,6 ± 0,134 
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with standard deviationW	+, = 0,13 ± 0,01. Data obtained from the XRD and 
TEM analysis are reported in Table 7.1. 
 
 
Figure 6. 6: A selected TEM micrograph of MNP-6, and the corresponding size distribution of diameter obtained by 
a statistic over several images; the average diameter is X-./ = 13,6 ± 2,1	34;the black thick line is the fitting to a log 
normal function with X+, = 13,7 ± 1,8	34 
 
Sample Crystal size (QR) Lattice Parameter Å S&'( (QR) S)* (QR) T)* 
MNP-6 15,6	 8,403(1) 13,6 ± 2,1	 13,7 ± 1,8	 0,130 
Table 6. 1: Crystal size and lattice parameter obtained from the XDR patter fit with the Pawley method using 
T.O.P.A.S.® software, for MNP-6. X-./ is the mean diameter obtained from statistical analysis of the size measured 
on TEM micrograph; S+, the mean diameter and W+,, standard deviation from the fit to a Log Normal distribution. 
As previously discussed high crystalline MNPs of this size are optimal candidate 
for nano-medical application. MNP-6 was coated with APPA by ligand 
exchange, and dispersed in water. The magnetic properties of MNP-6@APPA 
were investigated using a SQUID magnetometer, by recording the dependence 
of magnetization on temperature (ZFC-FC), and on the applied field at room 
temperature and 2,5 K. 
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The ZFC-FC, reported in Figure 6.7a, showed the typical behaviour expected 
for a MNPs system blocked at room temperature. Conversely, the hysteresis 
loop recorded at room temperature, (Figure 6.7 b), displays no magnetic 
irreversibility, indicating the MNP-6are superparamagnetic at room temperature 
on this time scale.  
 
 
Figure 6. 7: Magnetic properties of MNP-6: A) Temperature dependence of the ZFC-FC magnetizations, (empty and 
full symbols refer to ZFC and FC magnetizations, respectively); B) Magnetization recorded at room temperature; C) 
Hysteresis loop recorded at2,5	Y; D) Details of the hysteresis loop in the low field region. 
Figures 6.7 c and d, show the hysteresis loop recorded at low temperature and 
the low field detail, respectively, while the parameters extracted from the loop 
(saturation and remnant magnetisations and coercive field) are reported in table 
6.2. The MNPs saturate rapidly, reaching a high value both at low and high 
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temperature, 86	.4L/B and 80	.4L/B, respectively. Overall, MNP-6 showed 
notable magnetic properties for the desired applications, especially a high Z1. 
The coercive field of MNP-6 is similar to those previously recorded for MNPs 
coated with APPA. 
 
Sample b7	cdde (fRg/h) b7i,je (fRg/h) k8 (lf)	 b9&/b:&	
MNP-6 80,0 86,4 448 0,45 
Table 6. 2: Magnetic saturation, Z1 extrapolated from magnetization curves at room temperature (300 K) and low 
temperature(2,5 K); Coercive Field, \2, and remnant magnetizationZ3-/Z4- obtained fromthe hysteresis loop. Z1 is 
given as emu per g of magnetc material. 
 
The hyperthermic properties of aMNP-6water suspension, 5	4B/4?, were 
investigated by recording the kinetic curve during the application of an AMF 
(17	_o4, 183	_\î) as shown in Figure 6.8. The SAR value calculate with 
equation 8 chapter 3.1 was 124,0 ± 2,0	üBZ%, a heat power good enough for 
MFH treatments. 
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Figure 6. 8: : Temperature evolution of a MNP-6 water suspension (concentration 5	4B/4?) 
After verifying good magnetic characteristics and the hyperthermic efficiency of 
MNP-6 we proceeded with the functionalization with HFn(DOXO), following the 
same steps described in chapter 4.2.  
First, MNPs@APPA was reacted with the crosslinker in PBS suspension at pH 
7.2. After 30	4E3 the unreacted reagent was removed by magnetic precipitation 
of the MNPs@PEG, which was washed twice with H2OMilliQ. Then, HFn(DOXO) 
was added (0,50	µZ) in PBS solution at pH 7.2 and after 60	4E3 the excess of 
HFn(DOXO) was removed by washing with PBS(10X). MNP-HFn(DOXO) was 
magnetically precipitated and washed twice with H2OMilliQ. 
The functionalization yield in number of HFn(DOXO) for MNPs, evaluated by IPC 
analysis of Fe, was 3:1. The measurement of the magnetic properties indirectly 
confirms this result, Z1 being reduced by 20% both at 300	Y and 2.5	Y (from 79,8	.4L/B to 63,8	.4L/B at 300	Y and from 90,7	.4L/B to 73,7	.4/B at 2,5	Y, 
Figure 6.10). 
  152
 
Figure 6. 9: Low field detail of the hysteresis loop recorded at 2,5	Y, for MNP-6@APPA (black circles) and MNP-6-
HFn(DOXO)(red circles). 
 
Figure 6. 10: Magnetization recorded at room temperature for MNP-6@APPA (black circles) and MNP-6-HFn(DOXO) 
(red line). 
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6.2.2 Stability of the MNP-6-HFn(DOXO) 
Before performing the in vitro study, it is necessary to accurately verify the 
amount of DOXO actually carried per unit of system. This analysis is required to 
check the stability of DOXO into the HFn during the synthetic procedure. In 
addition, we wish to verify the behaviour of the MNP-HFn(DOXO) when exposed 
to the AMF, and particularly to detect if DOXO is partially released during the 
MFH treatment as result of protein denaturation due to heat.  
The quantity of DOXO loaded in the nano-system was evaluated by optical 
absorption measurements. Since, absorption of the magnetite in the 350 −650	34	⁄ range (Figure 6.11) is so intense that does not allow an easy evaluation 
of the absorbance of the anthracycline molecule, the inorganic component was 
removed by protein denaturation with hydrochloric-isopropylic solution and 
magnetic separation. 
 
 
Figure 6. 11: MNP suspensions absorption spectra, conc. 100 − 50 − 10 − 5	`B/4?. 
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From the absorbance at 532	34 we evaluated a concentration of DOXO 12	`Z, 
which, considering there are 3 HFn per MNP, corresponds to 60 molecules of 
DOXO per HFn. Thus, this data confirms the stability of the HFt (DOXO) during 
the functionalization process and over the time as reported by Falvo et al.10 
(Figure 6.12). 
 
 
Figure 6. 12: Acid solution of denatured protein absorption spectra compared to DOXO 12,5	`Z	solution. It is well 
evident the interference of. MNP impurity. In order to reduce the interference, we choose the 532	34	peak. 
The drug release tests under the AMF action was performed as follows: 1 mL 
of MNP-HFn(DOXO) suspension at concentration of 1 mg/mL was exposed to 
an AMF of 183	_\î frequency and 17	_o4Z% amplitude at body temperature 
(37	°G). The evolution of temperature is shown in figure 6.13.  
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Figure 6. 13: : Temperature evolution of a MNP-HFn(DOXO) water suspension under the application of an AMF. 
After 1h the temperature reached almost 49°C, a remarkable value well above 
the cell resistance. The magnetic material was then magnetically separated 
from the surnatant. The optical spectrum of the surnatant is shown in figure 
6.14. 
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Figure 6. 14: a) Absorption spectrum of surnatant; b) Doxo signal after the subctraction of the MNPs component. 
After subtraction of the signal of residuals MNPs, realized by spline interpolation 
of the bottom line, (Fityk 0.9.8 software), we determined that the drug released 
during hyperthermic treatments was equal to 4	`Z, which is ≈ 10	% of the 
DOXO contained within ferritins. Hyperthermic treatment seems therefore 
unable to promote full protein denaturation, particularly in view of the lower 
temperatures reached in the treatment. However, this does not represent a 
problem as, once internalized, the digestive action of cellular enzymes can 
cause the full release of the drug. Moreover, as previously pointed out, HFn are 
very heat-resistant13,14 but easily denaturise when the pH decreases.  
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6.2.3 In vitro test: internalization and antitumoural efficacy of the 
drug loaded nano-system 
The tests performed so far on MNP-HFn(DOXO) have shown chemical-physical 
and magnetic properties, stability, functionalization level, and hyperthermic 
efficiency comparable to those of the drug-free analogous. Thus, we proceeded 
with in vitro tests, which were performed on MDA-MB-231 breast cancer cells, 
following the same protocol described in scheme 5.1, These tests were 
performed in collaboration with Barbara Tenci and Dr. Lorenzo Di Cesare 
Mannelli at the laboratory of Farmacologia e Tossicologia Dip. Di Neuroscienze, 
Psicologia, Area del Farmaco e Salute del bambino (NEUROFARBA) 
dell’Università di Firenze. 
 
At first we performed the viability test by treating cells with increasing 
concentrations of MNP-HFn(DOXO) in order to find the best concentration of 
heat mediators which produces an hyperthermic effect without masking the 
possible synergy with the drug action. 400	Y cancer cells were trypsinizated 
and detached from the cultivation flask, and then suspended in 0,5	4? of 1:1 
mix of DMEM and physiological solution containing 5% BSA. Samples were 
incubated with	1 or 0,3	4B/4? MNP-HFn(DOXO), that correspond to 171, 57,1 
or	17,1	`Z of free DOXO for the other samples. After 3	ℎ of treatment, which 
corresponded to the time that would be required in a MFH experiment for 
incubation, field application, plus one hour of further incubation to increase the 
efficacy of DOXO, the samples were washed from the treatment and incubated 
for the viability test. As a control the test was also carried on cells incubated 
with the same concentration of HFn(DOXO), MNP-HFn and free DOXO.  
In figure 6.14, are shown the results of the MTT viability test performed after 48	ℎ. 
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Figure 6. 15: MTT MDA-MD-231 cells viability test 48h after the incubation with MNP-HFn (light grey bar); MNP-
HFn(DOXO) (dark grey bar); HFn(DOXO) (magenta bar); DOXO (purple bar). Each value is normalized to the 
corresponding control sample. 
Cells treated with MNP-HFn show no significant mortality, giving proof that, 
even after modification with PAS, MNP-HFn is biocompatibile. The culture 
incubated with DOXO alone show a dose dependent decrease in cell viability 
(38 − 20 − 5	%), which is explained by the systemic action of the drug in direct 
contact with the cells. The viability of cells treated with HFn (DOXO), instead, 
does not depend on the amount of drug, as it decreases for all samples of about 40%. That effect is justified by the release of the drug due to the internalized 
ferritin disruption. The absence of a dose-dependent is consistent with the 
internalization mechanism of HFn, within the 3	ℎ of incubation. Indeed, during 
this time the turnover of the receptors on the membrane is saturated, so that 
the amount of HFn(DOXO) internalized is the same. This result indirectly 
confirms that, as expected, only the HFn(DOXO) internalized into the cell release 
the drug payload. Finally, no effect was detected in cultures incubated with 
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MNP-HFn(DOXO). This can be attributed to a low degree of internalization of 
the nano-device. Indeed, when we verified the degree of internalization of MNP-
HFn by fluorescence microscopy we did not observe any relevant amount of 
MNP-HFn(DOXO) into the tumour cell.  
This unpredicted result may be justified considering the lower number of HFn 
attached at the MNP surface with respect to the unloaded counterpart. The 
presence of PAS in the HFn used to increase the DOXO load may have modified 
the capability of the protein to be grafted onto the MNPs, as the ratio 
HFn(DOXO):MNP (3: 1) is lower compared to HFn:MNP (4: 1 or 6: 1). The lower 
number of ferritin and the presence of PAS then could also affect the interaction 
between the TfR1 receptor and the nano-system, making its internalization 
more difficult.  
As a matter of fact, the lack of internalization on one hand, and the low dose of 
DOXO released during the hyperthermia treatment, hamper at present the in 
vitro validation of this nano-device as a multifunctional agent for the therapy of 
tumour.  
Future studies need to be focused on optimizing the synthesis of MNP-
HFn(DOXO) to increase the number of HFn and then the degree of 
internalization. Possibly strategies will be to select a HFn(DOXO) with different 
degree of enrichment of PAS or to use HFn(DOXO) genetically or chemically 
modified to provide them with a specific targeting agent for the selected cell 
line. 
 
 
 
 
 
 
 
 
  160
1. ARCAMONE, F., CASSINELLI, G. & FRANCESCHI, G. Structure and 
physicochemical properties of adriamycin (doxorubicin). Int. Syrup. 
Adriamycin 9–22 (1972). 
2. YOUNG, R. C., OZOLS, R. F. & MYERS, C. E. The anthracycline 
antineoplastic drugs. New Engl. J. Med.305, 139–153 (1981). 
3. Keizer, H. G., PINEDO, H. M., SCHUURHUIS, G. J. & JOENJE, H. 
DOXORUBICIN (ADRIAMYCIN): A CRITICAL REVIEW OF FREE RADICAL-
DEPENDENT MECHANISMS OF CYTOTOXICITY. 47, 219–231 (1990). 
4. Shen, J., Wolfram, J., Ferrari, M. & Shen, H. Taking the vehicle out of drug 
delivery. Mater. Today20, 95–97 (2017). 
5. Lehner, R., Wang, X., Marsch, S. & Hunziker, P. Intelligent nanomaterials 
for medicine: Carrier platforms and targeting strategies in the context of 
clinical application. Nanomedicine Nanotechnology, Biol. Med.9, 742–757 
(2013). 
6. Falvo, E. et al. Antibody-drug conjugates: targeting melanoma with 
cisplatin encapsulated in protein-cage nanoparticles based on human 
ferritin. Nanoscale5, 12278–12285 (2013). 
7. Ceci, P. & Falvo, E. A FUSION PROTEIN, A NANOPARTICLE COMPOSED 
BY A PLURALITY OF MONOMERS OF SAID FUSION PROTEIN, AND 
USES THEREOF. (2016). 
8. Vannucci, L., Falvo, E. & Ceci, P. Multifunctional Protein-Based 
Nanoparticles for Cancer Theranosis. 7, 231–253 (2014). 
9. Vannucci, L. et al. In Vivo Targeting of Cutaneous Melanoma Using an 
Melanoma Stimulating Hormone-Engineered Human Protein Cage with 
Fluorophore and Magnetic Resonance Imaging Tracers. 10, 1–12 (2014). 
10. Falvo, E. et al. Improved Doxorubicin Encapsulation and Pharmacokinetics 
of Ferritin − Fusion Protein Nanocarriers Bearing Proline, Serine, and 
Alanine Elements. (2016). doi:10.1021/acs.biomac.5b01446 
11. Bellini, M. et al. Protein nanocages for self-triggered nuclear delivery of 
DNA-targeted chemotherapeutics in Cancer Cells. 196, 184–196 (2014). 
12. Fracasso, G. et al. Selective delivery of doxorubicin by novel stimuli-
sensitive nano-ferritins overcomes tumor refractoriness. 239, 10–18 (2016). 
13. Fan, K. et al. Magnetoferritin nanoparticles for targeting and visualizing 
tumour tissues. Nat. Nanotechnol.7, 459–64 (2012). 
14. Uchida, M. et al. Targeting of Cancer Cells with Ferrimagnetic Ferritin Cage 
Nanoparticles. 312, 16626–16633 (2006). 
 
 
 
 
 
 161 
7. Conclusion and Perspective 
 
The aim of this research was the synthesis of a multifunctional device based on 
MNPs functionalized with ferritins, capable to target tumours and to act both 
for early diagnosis by MRI, and therapy of tumours by magnetic fluid 
hyperthermia. The originality of this work is the use of ferritin, that makes the 
final nano-device biocompatible, capable of being selectively internalized in the 
tumour cells and able to circulate for a long time in the bloodstream. Finally, a 
further advantage is provided by the possibility of exploiting the ferritin cavity 
as a container for the delivery of antitumoral drugs. 
To achieve this goal, we synthesized iron oxide MNPs by thermal 
decomposition of metalorganic precursors in high boiling solvent, namely, iron 
acetylacetonate in benzylether. This technique allowed us to produce quasi-
monodisperse, high-crystalline magnetite MNPs of controlled size, which are 
key features for the clinical application of MNPs. Moreover, we investigated the 
role of the different synthetic parameter in order to find the best condition to 
obtain inorganic core suited for the biomedical application. The high quality of 
the MNPs, such as the high magnetic saturation at room temperature were 
confirmed by magnetometric measurements, which also allowed us to describe 
the superparamagnetic behaviour of the samples.  
Functionalization of MNP surface was carried out exploiting a phosphonate 
ligand with a free amino group, which has a great affinity toward iron oxide, and 
gives both hydrophilicity and a binding site for the further functionalization with 
ferritin. The MNPs chosen as magnetic cores selected for the functionalization 
with ferritin are those which have showed the greatest hyperthermic capability 
in magnetic hyperthermia experiments and a better efficiency in increasing 
image contrast in MRI in comparison to commercial contrast agents, such as 
Endorem®. Furthermore, it is particularly relevant that the chosen MNPs 
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maintain the high hyperthermic efficiency even in a strongly viscous 
environment, as demonstrated by tests performed on agarose gel suspensions. 
This is a crucial result, indeed, since in the physiological environment like 
intracellular fluid and extracellular matrix, i.e. the final target of the nano-device, 
no mechanical rotation is allowed. 
Ferritins were then bound to the MNPs thanks to a heterobifunctional PEG 
ligand that selectively reacts with the amino groups on the surface of the MNP 
and the thiol groups onto the ferritin. The success of the MNP-HFn conjugation 
was confirmed by using different techniques as electrophoresis on agarose gel, 
DLS, AFM, ICP, CHN and magnetometric measurements. In particular, DLS 
data showed that the hydrodynamic radius of the MNP-HFn is lower than 100 
nm, ideal for the colloidal stability of the water suspension and for a long 
circulating half-life, as confirmed by in vitro and in vivo experiments.   
The MNP-HFn system was tested both in vitro and in vivo to verify its 
antitumoural efficiency. In vitro tests were carried out on prostate and breast 
cancer cell lines, two tumours that represent almost the 25% of all cancer cases 
and that overexpress the transferrin receptors TfR1, able to internalize the 
ferritin into the cytosol. The internalization capability of our system was 
confirmed by confocal microscopy of cells incubated with rhodamine-labelled 
MNP-HFn sample. Then, the cells samples were exposed to AMF of intensity 
and frequency and for exposure times similar to those used in clinical trials. We 
found that MNP-HFn was able to efficiently kill cancer cells only when its 
concentration allowed reaching and maintaining the temperature of the cell 
culture at 43°. To better understand this behaviour, we verified the thermal 
damages suffered by cells when heated at different temperature without the 
application of an AMF. We found that the damages produced when the cells 
are heated up to 44° are lower than those observed in MFH treatments and 
thus, we cannot exclude that internalized MNPs provide an additional 
contribution to cell death by producing a direct inner damage, which enhances 
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the effect of the treatment. This is an important indication that deserves further 
in-depth study. The knowledge of the mechanism of cell death is also pivotal to 
establish the best strategy to follow for the administration of the nano-device. 
If internalization is fundamental to enhance the treatment efficiency, then an 
active targeting that permits to cross the cell membrane has to be preferred, 
while it becomes less relevant the nano-device accumulation in the extracellular 
matrix obtained by EPR effect. 
Finally, we present the results of the preliminary in vivo investigation realized on 
mice inoculated with Enrilch tumour cells, a mice cancer type of mammary 
origin. MNP-HFn were injected via intravenous or intratumoural administration 
in mice, which were then exposed to an AMF every two days for ten days. The 
tumours size was checked along the following months together with mice 
general clinical conditions. This investigation has clearly shown that the 
administration of MNP-HFn, even when systemic (intravenous application), did 
not cause any adverse effect on mice in terms of biochemistry and 
haematological alteration. Most importantly, the application of an AMF even of 
very low amplitude, induced a partial tumour regression, at last during the first 
days after the treatments. These promising preliminary results must be 
confirmed by further analysis: histological analysis, genotoxicity analysis, 
cytotoxicity analysis and microtomography analysis are currently in progress 
and will also give us information on the fate of the nano-device providing the 
biodistribution in the mice. Even if partial, the obtained results made the nano-
system synthesized in this work an extremely appealing platform for the therapy 
of tumours such as breast cancer. 
The final part of this work is dedicated to the “step further” of the ferritin 
capabilities exploiting, which consists in enhancing the antitumoral activity of 
the MNP-HFn system using HFn, PAS enriched, filled with a chemotherapic 
drug, doxorubicin. Following a procedure similar to that described for MNP-
HFn, we successfully synthesized the drug loaded analogue, MNP-HFn(DOXO). 
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We proved that this system releases DOXO in an acid environment, such that 
of lysosome, while it is extremely stable during the hyperthermia application. 
Unfortunately, this new system, unlike the previous one, was not efficiently 
internalized by the cancer cells, preventing us from proceeding with the in vitro 
evaluation of the combined antitumoural activity. We hypothesize that the lower 
number of ferritin and the different HFn structure could affect the interaction 
between the cell membrane and the nano-system, making its internalization 
more difficult. Different strategies must be investigated in the future in order to 
improve the internalization of MNP-HFn(DOXO). For example we plan to use a 
HFn(DOXO) with different degree of enrichment of PAS or a HFn(DOXO) 
genetically or chemically modified which exposes a specific targeting agent for 
the selected cell line. 
In conclusion, in this thesis we have presented a novel hybrid magnetic nano-
device for theranostic application in biomedicine. Although we have 
demonstrated the great potential of this system, there are still many aspects 
which deserve further investigation. In particular, further studies will be 
dedicated to the damages suffered by the cells under MFH application and to 
distinguish the thermal effect from the contribution from internalized magnetic 
cores. On the other hand, a deep analysis of the result of in vivo tests will allow 
clarifying the actual potentialities and possible issues related to the use of MNP-
HFn, with a special attention to the biodistribution and genotoxicity. Finally, we 
will investigate the drawbacks encountered during the functionalization of the 
MNPs with HFn(DOXO), revising the synthesis and, once improved the 
internalization degree, we will assess its antitumoural activity. 
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8. Materials and methods  
8.1. Materials  
All chemicals were of analytical quality purchased from Sigma-Aldrich Co.. 
Water was deionized and filtered with a Milli-Q System (Merck Millipore Co., 
Germany). Except for SM(PEG)12 Crosslinker purchased from ThermoFisher 
Scientific. 
 
8.2. Methods   
8.2.1 Preparation of Àfcl® MNPs  
The iron oxide MNPs were synthesized by thermal decomposition of metal-
organic precursors in high boiling solvents, in the presence of surfactant. In a 
typical reaction, Iron(III) acetylacetonate (2,83	B, 8,0	44=>), Oleylamina 
(10,72	B,	40	44=>) and Oleic Acid (11,23	B, 8,0	44=>) were dissolved in 
Benzilether (100 − 1104?) stirred and purged under nitrogen flow for 15	4E3 at 
r.t.; the mixture was heated at 200	°G for 30	4E3 and then to 300	°G for a period 
of time sufficient to produce nanoparticle of the desired size. Indeed, at 200	°G 
we have the production of the monomer and the making of crystal seeds 
(nucleation phase), while at 300	°G the dimension of the seeds increases due to 
the supersaturation of the monomer (growth phase). The mixture was cooled 
down to r.t., the black MNPs precipitate was magnetically separated, cleaned 
three times with ethanol and suspended in Toluene. 
 
8.2.2 Coating exchange of Àfcl® MNPs  
A coating exchange was performed using 3-AminoPropylPhosphonic Acid 
(APPA) a ligand that permit both a firm covalent bond between the MNPs and 
the ligand itself and give a free amino group for the further functionalization. 
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Typically, 44? of Toluene suspension of MNPs (10	4B/4?	-."/#) were mixed 
with 44? of dichloromethane solution of APPA (10	4B/4?) and 
Tetramethylammonium hydroxide (TMAOH, 10	4B/4?) and sonicated for one 
hour. Then MNPs were magnetically separated, cleaned with ethanol and 
suspended in water. 
 
8.2.3 Functionalization of Àfcl® MNPs with HFn 
The covalent junction between HFt and MNPs@APPA were obtained by using 
a heterobifunctional crosslinker SM(PEG)12 (Thermofischer NHS-PEG-MAL) in 
witch N-hydroxysuccinimide (NHS) ester react specifically with free amino 
groups onto MNPs side while maleimide (MAL) group react specifically with the 
thiol group onto the HFt molecules. The two reactive group were separated with 
a 7,5	_∆6 polyethylene glycol (PEG) spacer was used to improve water solubility 
of the conjugate, and to minimize possible steric hindrance between APPA 
MNPs and ferritin molecules during conjugation. MNP-HFt conjugates were 
prepared by a two-step reaction scheme. First, MNPs@APPA (0,1	µZ in amino 
groups) was reacted with 50 − ~=>X molar excess of the crosslinker in PBS 
suspension at pH 7.4 at room temperature sonicating for 30 min. The excess 
(non reacted) reagent was removed by magnetically precipitating the 
MNPs@PEG and cleaned with H2OMilliQ twice. Second, cysteine-containing HFt 
was added (0,25	µZ, final concentration) in PBS solution at pH 7.4, and 
sonicated for 60 min at room temperature allowing to react with the MAL groups 
present on the modified APPA NPs molecules. The excess (non reacted) of HFt 
was removed by washing the MNP-HFt with PBS magnetically precipitating the 
MNP-HFt and cleaned with H2OMilliQ twice. The MNP-HFt samples were 
maintained sterile heating at 60	°G for 20	4E3. 
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8.2.4 Functionalization MNP-HFn with rhodamine 
Exploiting the free amino groups of lysine onto the HFt surface, MNP-HFt were 
been labelled with NHS-Rhodamine to be used as fluorescent dye and verify 
the capability of the sample to be internalized by the cell. MNP-HFt-Rhd were 
been prepared by adding NHS-Rhodamine DMSO solution (20	4Z, final 
concentration) to a MNP-HFt 0,5	4B/4?	PBS suspension and sonicating for 30	4E3. The excess (non reacted) dye was removed by magnetically 
precipitating the MNP-HFt-Rhd and cleaned with H2OMilliQ four times. 
 
8.3 Characterization methods  
X-Ray Diffraction 
Powder X-ray diffraction (XRD) measurements were carried out using a Bruker 
D8 Advance diffractometer equipped with Cu Kα (1,54178	Å) radiation and 
operating in fl − 2fl Bragg−Brentano geometry at 40	_m and 40	4o. Lattice 
parameters were evaluated on averaging over (400), (511) and (440) peaks. The 
determination of the mean crystallite diameter, d, was performed using the 
Scherrer equation,X	 = 	 (0.9⁄)/(‡	7=Mfl), where λ is the wavelength of the 
incident X-ray (1,54178	Å), fl the diffraction angle, and ‡ the full-width at half-
maximum. The quantification of the phase percentage was obtained analyzing 
the diffraction pattern by the Rietveld method with TOPAS software.  
 
TEM 
The average diameter and size distribution of MNPs were determined from 
Transmission Electron Microscopy (TEM) images recorded using a CM12 
PHILIPS transmission electron microscope operating at 100	_m using a LaF6 
source. Samples were prepared by drop drying a dilute toluene solution of 
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MNPs onto 200 mesh carbon-coated copper grids. The recorded micrographs 
were processed by means of the iTEM TEM Imaging Platform software 
(Olympus), and were further analysed with the FIJI open software. The mean 
diameter and size distribution of the sample was obtained from a statistical 
analysis over 800 MNPs.  
 
Electrophoresis 
The bond between MNPs and HFt were obtained by using agarose gel 
electrophoresis experiments. In order to resolve the MNP-HFt complexes, 
electrophoresis was carried out on 1	% agarose gels in 0,04	Z Tris-acetate 
buffers at a constant voltage of 80	m	at r.t.. The gels were unstained or stained 
with Coomassie blue to visualize MNPs and protein band relative contributions. 
Atomic Force Microscopy  
Atomic Force Microscopy (AFM) measurements were carried out using a NT-
MDT Solver P47 PRO; samples were drop-casted on a fresh prepared mica 
surface and studied with a AFM noncoated Si goldbackcoated 10 (NSG10) 
probe in tapping mode. Images were elaborated with WSxM software. 
 
Dynamic Light Scattering 
Dynamic Light Scattering (DLS, Malvern Zetasizer ZS, Malvern Instruments Ltd., 
UK) measurement, Z-pot analysis and size distribution, were carried out 
on	0,5	4B/4>	suspension of the samples. 
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Fluorescence spectroscopy 
The presence of Rhodamine were been verify by recording in 555 − 655	34 
interval the UV spectra (⁄∗ = 550	34 exciter) of MNP-HFt-Rhd diluted solution 
(LS55 Luminescence Spectrometer, Perkin Elmer, Massachusetts U.S.). 
 
UV-Vis Absorbance spectroscopy 
The absorbance analysis were been performed with a V-670 JASCO 
spectrophotometer, with a quartz vial (> = 1	74), recording the signal in the 
range 300 − 700	34. 
 
ICP-AES 
The quantitative analysis of iron content was carried out with an atomic 
emission spectrometer coupled with a inductively coupled plasma torch (ICP-
AES, Varian 720-ES) at the Department of Analytical Chemistry of the University 
of Florence from the group research by Prof. R. Udisti. To analyse iron content, 
powder samples were digested with 1	4? of \é/", 1	4? of \G> and 1	4? of \$/$ and the solution is diluted to 20	4? with the addition of Ge (1	ÜÜ4) as an 
internal standard. The calibration standard was prepared for serial dilution of a 
commercial standard solution of Fe 1000	4B/4?. The wavelength used for the 
determination of -. is 238,204	34 while the line ·. was used at 209,426	34. 
The operating conditions were optimized to obtain maximum signal strength. 
 
8.4 Magnetic Characterization and SAR evaluation  
Magnetic measurements were performed using a Quantum Design MPMS 
SQUID magnetometer operating in the 1,8– 350	Y	temperature range and with 
an applied field up to 50	_/.. Measurements were performed on pressed 
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powder of SPION sample. All data were corrected for the diamagnetic 
contribution of the sample holder, and were normalized to the amount of 
magnetic material as evaluated from elemental analysis. Zero Field Cooled–
Field Cooled (ZFC/FC) curves were obtained by measuring the temperature 
dependence of the magnetization applying a probe magnetic field (50	/.), after 
cooling the sample in the absence (ZFC) or in the presence (FC) of the field. A 
rough estimate of TB value accuracy is given by the half interval between the 
temperatures of two subsequent acquisition points, i.e., 2,5	Y. The field 
dependence of the magnetic moment (M vs. H) was measured cycling the field 
between ±	50	_/. at 2,5	Y and 300	Y. The accuracy of HC, MR and MS 
evaluation can be estimated as low as 3	%. 
The evaluation of Specific Absorption Rate (SAR) was performed through 
calorimetric measurements by recording temperature kinetics of samples 
exposed to an alternating magnetic field. SAR was evaluated both for water 
suspension of MNPs and MNP-HTt, than for agarose gel dispersion of MNPs in 
order to simulate the human tissue environment. Measurements were 
performed adapting a commercial setup, composed by a 6 kW Fives Celes 
power supply, a water-cooled induction coil and a series of variable capacitors 
(420	3-	to	4,8	`-) for setting the required frequency. Such resonant RLC circuit 
is able to produce an alternating magnetic field in the range of 50–400	_\î and 
with amplitude up to 19,1	_o4Z%. The frequency and field amplitude values 
used in this work (183	_\î, 17	_o4Z%) were chosen in order to operate under 
the physiological limit, \s < 5 ∙ 10_o	4Z%MZ%, beyond which deleterious 
responses of living tissues are observed (Figure 8.1). The sample was placed in 
the middle of the induction coil, inside a polystyrene sample holder placed in a 
glass Dewar connected to a glycol thermal bath in order to isolate the sample 
bath from the thermal gradient of the coils and from the environment (Figure 
8.2). The real amplitude of the magnetic field was determined by a AMF Life 
Systems high frequency probe. Measurements of the sample temperature were 
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performed by an optical fiber thermometer connected to a digital temperature 
recorder (Fotemp). The SAR values were calculated using the equation nop =	ÑuquÖuqÜá ∙ à-à? , where °J is the temperature increase in the interval of time °C, 46` 
is the total mass of -."/#, 4< is the mass in grams of the i-species and 7< is its 
specific heat. The sum is extended to all the i species involved in the heat 
exchange. Since the measurements are carried in non adiabatic conditions, the °J °C⁄  values were extrapolated for C ≈ 0 from temperature kinetic curves, by 
considering the initial slope. 
 
Figure 8.1: Power supply MP6-400 6kW®, Fives Celes Inc. and FoTemp optical fiber 
thermometer. 
 
Figure 8.2: Detail of the Ethylene glycol thermostated system. 
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Figure 8.3: Field simulation output for the 6 windings coil, at 183 kHz of frequency and 16 kA/m 
of intensity. 
 
8.5 In vitro biocompatibility and magnetic fluid hyperthermia 
experiments 
In vitro tests to evaluate the biocompatibility of the MNP-HFt and the efficiency 
of the magnetic hyperthermic treatment were carried on Prostate cancer cell 
(PC3) and Breast cancer cell (MDA-MB-231), obtained from the American Type 
Culture Collection (Rockville, MD). The experimental design was based on 
previously published investigations analysing the in vitro hyperthermic efficacy 
of magnetic colloids1, cells were cultured in high glucose Dulbecco's modified 
Eagle's medium (DMEM) supplemented with 10	% fetal bovine serum (FBS; 
Gibco, Invitrogen, Italy) in a 5	% G/$	atmosphere at 37	°G. Medium contained 2	4Z L-glutamine, 100 âäq+ penicillin, and 100 AÅq+streptomycin (Sigma, 
Germany). Cells were trypsinized with Tripsin-EDTA solution 1 for 5	min	and 
then neutralized with culture medium. A total of 4 ∙ 104 cells were suspended in 400	`? of saline solution  plus 5	%	bovine serum albumine (BSA) to favour a 
homogeneous suspension and incubated for	60	4E3 at	37°G in the presence or 
 
 
 175 
in the absence of MNP-HFt 3 − 1 − 0,3	4B/4?. An oscillating magnetic field of 17,0	_o4Z% and 183	_\î was applied to the cell suspension for 1	ℎ=La. 
Alternatively, cell suspensions were centrifuged at 1400	aÜ4 for 5	4E3	to 
separate cells from the unbound MNP-HFt. Then cell pellets were re-suspended 
in 400	`?	of saline solution plus 5	%	¥no	and subjected to the oscillating 
magnetic field. For this purpose, cell samples were placed in the middle of the 
induction coil, inside a polystyrene sample holder placed in a glass Dewar 
connected to a glycol thermal bath in order to keep the system at 37	°G and 
avoid thermal gradient of the coils and from the environment surroundings. After 
the exposure to the magnetic field, cells were centrifuged at 1400	aÜ4 for 5	4E3. 
Cells were washed twice in saline solution and suspended in 400	`? of culture 
medium. A volume of 40	`?	of the cells suspension was used to perform Trypan 
Blue assay. Thirty microliters of the cells suspension was plated into 96	».>>M 
culture plates and the sample was incubated in 5	%	G/$	atmosphere at 37	°G; 48	ℎ after, MTT assay was performed.  
 
Trypan Blue 
Trypan Blue Assay, PC3 and MDAMB231 cells were diluted with 0,4	%	trypan 
blue (Sigma-Aldrich, Italy), pipetted onto a Burker chamber and counted under 
a microscope at 40 magnifications. Live cells excluded the dye, whereas dead 
cells admitted the dye and consequently stained intensely with trypan blue. The 
number of viable cells for each experimental condition was counted.  
 
MTT 
MTT Assay. Cell viability was evaluated by the reduction of 3-(4,5-
dimethylthiozol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma-Aldrich, 
Italy). A total of 1	4B/4? of MTT was added into each well and the samples 
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were incubated for 30	4E3	at 37	°G. After washing, the formazan crystals were 
dissolved in 100	`? of dimethyl sulfoxide. The absorbance was measured at 550	34.  
 
Fluorescence microscopy 
Cell were incubated for 1	ℎ in DMEM in presence of HFn-Rhd in a petri plate, 
after removing the culture media congaing the fluorescent substance and 
replaced with fresh DMEM cell were analysed. The fluorescence microscope 
used was a Widefield: Leica AM6000, equipped with filter set N3 or N21 (for 
the rhodamine signal) and a Leica DFC350FX camera. 
 
Confocal microscopy 
Cell were incubated for 1 h in DMEM in presence of MNP-HFn-Rhd in a petri 
plate, after removing the culture media congaing the fluorescent substance and 
replaced with fresh DMEM celle were analysed. The confocal microscope used 
was a Leica SP2-AOBS, using a LASER exciter at ⁄∗ = 561	34, taking images 
at different focal plane. 
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altri componenti del LAMM: la Prof.ssa Roberta Sessoli, il Prof. Lorenzo 
Sorace, Il Prof. Federico Totti, Pine, Pone, Beppe, Poggio, Giulia, Marie-
Emmanuelle, Irene, Brunetto, Matteo B., Matteo A., Donata, Pamela e 
Beatrice. 
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Ringrazio poi i miei genitori e la mia sorellina in primis, e il resto della mia 
grande Famiglia TUTTA che mi è sempre stata vicina e mi ha supportato 
sempre e comunque, senza il loro sostegno mi sarei perso combinando 
poco o nulla. 
Un grazie anche ai miei amici di una vita, con i quali ho condiviso tanti 
momenti preziosi e che mi hanno aiutato a crescere: Checco, Leo, Lore, 
Marco, il Don, il Gentili, Faggio, Beppe la SFL-HateSquad, gli ex SCOUT e 
anche a tutti coloro che ho imparato a conoscere più di recente, B-team 
annessi e connessi. 
Ultima ma solo perché la più importante voglio ringraziare la mia futura 
moglie: Diletta. Grazie per essermi stata sempre vicina, per il tuo costante 
supporto e amore che ha allietato anche i giorni più duri quando tutto 
sembrava non avere un senso, come potrei essere arrivato dove sono senza 
di te? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
